Articles

Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis

COVID-19 Cumulative Infection Collaborators*

Summary
Background Timely, accurate, and comprehensive estimates of SARS-CoV-2 daily infection rates, cumulative infections, the proportion of the population that has been infected at least once, and the effective reproductive number (R ) effective are essential for understanding the determinants of past infection, current transmission patterns, and a population's susceptibility to future infection with the same variant. Although several studies have estimated cumulative SARS-CoV-2 infections in select locations at specific points in time, all of these analyses have relied on biased data inputs that were not adequately corrected for. In this study, we aimed to provide a novel approach to estimating past SARS-CoV-2 daily infections, cumulative infections, and the proportion of the population infected, for 190 countries and territories from the start of the pandemic to Nov 14, 2021. This approach combines data from reported cases, reported deaths, excess deaths attributable to COVID-19, hospitalisations, and seroprevalence surveys to produce more robust estimates that minimise constituent biases.
Methods We produced a comprehensive set of global and location-specific estimates of daily and cumulative SARS-CoV-2 infections through Nov 14, 2021, using data largely from Johns Hopkins University (Baltimore, MD, USA) and national databases for reported cases, hospital admissions, and reported deaths, as well as seroprevalence surveys identified through previous reviews, SeroTracker, and governmental organisations. We corrected these data for known biases such as lags in reporting, accounted for under-reporting of deaths by use of a statistical model of the proportion of excess mortality attributable to SARS-CoV-2, and adjusted seroprevalence surveys for waning antibody sensitivity, vaccinations, and reinfection from SARS-CoV-2 escape variants. We then created an empirical database of infection-detection ratios (IDRs), infection-hospitalisation ratios (IHRs), and infection-fatality ratios (IFRs). To estimate a complete time series for each location, we developed statistical models to predict the IDR, IHR, and IFR by location and day, testing a set of predictors justified through published systematic reviews. Next, we combined three series of estimates of daily infections (cases divided by IDR, hospitalisations divided by IHR, and deaths divided by IFR), into a more robust estimate of daily infections. We then used daily infections to estimate cumulative infections and the cumulative proportion of the population with one or more infections, and we then calculated posterior estimates of cumulative IDR, IHR, and IFR using cumulative infections and the corrected data on reported cases, hospitalisations, and deaths. Finally, we converted daily infections into a historical time series of Reffective by location and day based on assumptions of duration from infection to infectiousness and time an individual spent being infectious. For each of these quantities, we estimated a distribution based on an ensemble framework that captured uncertainty in data sources, model design, and parameter assumptions.

Lancet 2022; 399: 2351-80
Published Online April 8, 2022 https://doi.org/10.1016/ S0140-6736(22)00484-6
See Comment page 2326
*Collaborators listed at the end of the Article
Correspondence to: Ryan M Barber, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA 98195, USA rmbarber@uw.edu

Findings Global daily SARS-CoV-2 infections fluctuated between 3 million and 17 million new infections per day between April, 2020, and October, 2021, peaking in mid-April, 2021, primarily as a result of surges in India. Between the start of the pandemic and Nov 14, 2021, there were an estimated 3·80 billion (95% uncertainty interval 3·44-4·08) total SARS-CoV-2 infections and reinfections combined, and an estimated 3·39 billion (3·08-3·63) individuals, or 43·9% (39·9-46·9) of the global population, had been infected one or more times. 1·34 billion (1·20-1·49) of these infections occurred in south Asia, the highest among the seven super-regions, although the sub-Saharan Africa super-region had the highest infection rate (79·3 per 100 population [69·0-86·4]). The high-income super-region had the fewest infections (239 million [226-252]), and southeast Asia, east Asia, and Oceania had the lowest infection rate (13·0 per 100 population [8·4-17·7]). The cumulative proportion of the population ever infected varied greatly between countries and territories, with rates higher than 70% in 40 countries and lower than 20% in 39 countries. There was no discernible relationship between Reffective and total immunity, and even at total immunity levels of 80%, we observed no indication of an abrupt drop in R , effective indicating that there is not a clear herd immunity threshold observed in the data.

Interpretation COVID-19 has already had a staggering impact on the world up to the beginning of the omicron (B.1.1.529) wave, with over 40% of the global population infected at least once by Nov 14, 2021. The vast differences in cumulative proportion of the population infected across locations could help policy makers identify the transmissionprevention strategies that have been most effective, as well as the populations at greatest risk for future infection.

www.thelancet.com Vol 399 June 25, 2022

2351

Articles

This information might also be useful for targeted transmission-prevention interventions, including vaccine prioritisation. Our statistical approach to estimating SARS-CoV-2 infection allows estimates to be updated and disseminated rapidly on the basis of newly available data, which has and will be crucially important for timely COVID-19 research, science, and policy responses.

Funding Bill & Melinda Gates Foundation, J Stanton, T Gillespie, and J and E Nordstrom.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
Measuring SARS-CoV-2's daily infection rate, cumulative infections, and the proportion of the population with one or more infections is essential for understanding the determinants of past transmission, identifying ongoing inequities, predicting future trajectories of the COVID-19 pandemic, and, in theory, prioritising vaccination allocations. Daily infections are also the crucial input into

measuring the changing effective reproductive number (R , effective the number of subsequent infections caused by a new infection).1-3 A robust assessment of Reffective by day in each location is useful to help evaluate the effect of the wide range of non-pharmaceutical interventions that have been deployed during the pandemic. The Reffective over time is also a crucial input into future forecasts of COVID-19.4 Cumulative infections can help us identify

Research in context
Evidence before this study This study was conceptualised and developed from the start of the pandemic to fill a void in the provision of timely estimates of SARS-CoV-2 infections for tracking the pandemic and to provide inputs to epidemiological models of transmission. Several research groups have estimated SARS-CoV-2 daily or cumulative infections in select locations at specific points in time. For example, the US Centers for Disease Control and Prevention estimates cumulative infections by approximating the infection- detection ratio (IDR) using assumptions about the portion of the population who will seek care. The Serotracker project reports on the universe of seroprevalence surveys and some attributes of these surveys, but it does not make estimates of cumulative infections based on these data. Noh and Danuser (2021) used reported deaths and published estimates of the infection-fatality ratio (IFR) to estimate cumulative infections for US states and select countries. To our knowledge, however, no source has provided estimates, either periodic or regularly updated, of global daily and cumulative SARS-CoV-2 infections at this resolution (399 administrative units).
Added value of this study This study is the first comprehensive analysis of global daily and cumulative SARS-CoV-2 infections to date and improves upon previous infection estimation strategies in several important ways. First, we combined three approaches that have been used to estimate daily infections: cases divided by the IDR, hospitalisations divided by the infection-hospitalisation ratio (IHR), and deaths divided by the IFR. Combining these estimates gave us a more robust estimate of daily infections that was less susceptible to biases within and between each type of measure. Second, estimates of total COVID-19 deaths derived from a comprehensive assessment of excess mortality and a statistical estimate of the portion of excess mortality directly due to COVID-19 allowed for more meaningful interpretation of spatial heterogeneity in total COVID-19 mortality rates. Third, we used a systematic analysis of available seroprevalence data matched in

space and time to cases, hospitalisations, and deaths to empirically estimate the IDR, IHR, and IFR. Because the IHR and IFR are profoundly age related, we also estimated agestandardised ratios for these quantities. Fourth, for locations without seroprevalence surveys, we used statistical models based on the available empirical data and the testing of a wide range of covariates to predict the IDR, IHR, and IFR. Fifth, we used daily infections to estimate cumulative infections and, with assumptions on cross-variant immunity, the cumulative number of individuals with one or more infections, as well as posterior estimates of cumulative IDR, IHR, and IFR. Sixth, we incorporated corrections to the primary data into the analysis to deal with known biases such as waning antibody test sensitivity. Seventh, our ensemble model reflects the uncertainty of the data sources, model design, and parameter assumptions included in the analysis. Finally, the methods developed to triangulate on daily infections, cumulative infections, and the proportion of the population infected once or more than once have been developed into easily applied statistical code, so estimates can be shared and updated rapidly and iteratively on the basis of the frequency of newly reported data.
Implications of all the available evidence SARS-CoV-2 has been extremely widespread, causing 3·80 billion (95% uncertainty interval 3·44-4·08) infections and reinfections as of Nov 14, 2021, infecting 43·9% (39·9-46·9) of the world's population. The proportion of the population infected has varied greatly across countries, suggesting that host immunity characteristics and national and local policies play a crucial role in determining patterns of transmission. Our comprehensive modelling approach provides a database of daily infections and effective reproductive number by location from the beginning of the pandemic to Nov 14, 2021, which can be used to develop insights into the determinants of transmission, identify ongoing inequities, establish standards for vaccine prioritisation, and more.

2352

www.thelancet.com Vol 399 June 25, 2022

Articles

which nations and communities have been able to keep transmission at lower levels, potentially creating the opportunity to learn from these success stories. Finally, a sound measurement of the proportion of the population ever infected could help to identify which communities are at greater risk of future transmission and might be a factor that should be considered in vaccine prioritisation.5
Several studies have estimated cumulative infections in select countries at specific points in time.6-9 Some of these studies have used seroprevalence surveys, while others have made estimates of infections by assuming a particular infection-detection ratio (IDR).7,10-12 One study estimated infections in the USA and other select countries,13 and other studies have done multinational systematic reviews and meta-analyses of seroprevalence surveys.14,15 The fundamental problem in all of these analyses is that each of the data series observed has potential biases: reported cases capture only a portion of infections, and this portion will be a function of the availability of testing; reported deaths capture only a subset of total COVID-19 deaths, and the infection-fatality ratio (IFR) can vary widely over time and across locations;16-19 the proportion of patients with an infection who are admitted to hospital can also vary over time and location; and seroprevalence surveys can be influenced by sampling design, waning of sensitivity of antibody tests, and vaccination rates. Few studies have combined data from reported cases, reported deaths, hospitalisations, and seroprevalence surveys to triangulate daily infections, and WHO only routinely reports confirmed cases, not estimated infections.20 The use of such sources of incomplete, biased, and heterogeneous case data uncritically in research, science, and policy will result in inferences confounded to unknown levels by these known problems.
In this study, we present an approach to estimating past SARS-CoV-2 daily infections, cumulative infections through Nov 14, 2021, and the proportion of the population with one or more infections on the basis of reported cases, total deaths attributable to COVID-19, hospitalisations, and seroprevalence surveys. This approach attempts to deal with the biases in each of these measures and use them all to triangulate daily infections. With this statistical approach to the fusion of these data streams, we aimed to provide a method that can be applied on a rapid and ongoing basis, so that these estimates remain maximally relevant for research, science, and policy and can be immediately and freely available. Importantly, we incorporated various sources of uncertainty in daily infections into the analysis to help informed assessment of the variation in space and time of the fidelity of the estimates.
Methods
Overview We derived comprehensive global estimates of daily and cumulative SARS-CoV-2 infections for the duration of the COVID-19 pandemic, using the heterogeneous universe of reported epidemiological data (iteratively curated,

corrected, and calibrated into an internally complete and consistent time series at national and subnational levels) to further timely research, discovery, and policy inference. Our approach can be divided into seven steps, which are applied by use of an ensemble model framework. First, we developed a dataset of reported COVID-19 cases, total COVID-19 deaths, and hospitalisations (where available), corrected for known biases such as lags in reporting. Second, we identified representative SARS-CoV-2 sero­ preval­ence surveys that could be used to create a database of cumulative infections and adjusted them for waning antibody sensitivity, vaccinations, and reinfection from escape variants. Third, using adjusted seroprevalence survey data matched to cases, hospitalisations, and deaths, we created an empirical database of IDRs, infection- hospitalisation ratios (IHRs), and IFRs. Fourth, for locations without seroprevalence surveys and to estimate a complete time series for each location, we developed statistical models to predict the IDR, IHR, and IFR by location and day, as a function of a wide range of covariates. Fifth, three series of estimates of daily infections (cases divided by IDR, hospitalisations divided by IHR, and deaths divided by IFR) were combined into a more robust estimate of daily infections. Sixth, we used the combined time series of daily infections to estimate cumulative infections and the cumulative proportion of the population with one or more infections, and calculate posterior estimates of cumulative IDR, IHR, and IFR. Seventh, we converted daily infections into a historical time series of Reffective by location and day, on the basis of assumptions of duration of the period from infection to infectiousness and time an individual spent being infectious. Estimates are given for all ages and both sexes combined for 190 countries and territories, and for subnational locations in ten of those countries, aggregated into 21 regions, seven super-regions,21 and globally, from the start of the COVID-19 pandemic through Nov 14, 2021.
This study complies with the Guidelines for Accurate and Transparent Health Estimates Reporting recommendations (appendix 1, section 2).22 All code used in the analysis can be found online.
Ensemble framework Our model system includes many component parts that are inherently uncertain, ranging from input data sources and parameter assumptions to model specification. To account for this, we developed an ensemble framework wherein we varied the data and model settings across 100 iterations of the analysis, which were then run independently to yield 100 estimates of infections. These sources of uncertainty include seroprevalence survey error; bootstrapped samples of our seroprevalence database; estimates of seroreversion rates; estimates of total COVID-19 mortality; parameterisation of crossvariant immunity, increased risk of hospitalisation and death from non-ancestral SARS-CoV-2 variants, and durations associated with COVID-19 natural history;

See Online for appendix 1
For the analysis code see https://github.com/ihmeuw/ covid-historical-model and https://github.com/ihmeuw/ covid-model-infections

www.thelancet.com Vol 399 June 25, 2022

2353

Articles

covariate selection and specification of statistical models of the IDR, IHR, and IFR; and triangulation of infections on the basis of cases, hospitalisations, and deaths (more details regarding the ensemble framework in appendix 1, section 9).

See Online for appendix 2

Data inputs and corrections Data of reported cases were obtained largely from Johns Hopkins University (Baltimore, MD, USA),23 with exceptions and additions noted in appendix 1 (section 4.1) and appendix 2 (section 4). Hospital admissions were largely sourced from national databases such as that of the Department of Health and Human Services (HHS) in the USA and the Secretaria de Vigilância em Saúde in Brazil (for an exhaustive list see appendix 2, section 1). Deaths were based on reported deaths data from Johns Hopkins University23 and various national sources from locations where data inconsistencies were evident in the Johns Hopkins University datasets (more details in appendix 1, section 4.3, and appendix 2, section 2). To account for the prevalent issue of under-reporting in COVID-19 deaths, we applied a scalar of reported to total COVID-19 deaths in our analysis. Total COVID-19 deaths, as defined by WHO, are all deaths where the deceased individuals were actively infected with SARS-CoV-2 at the time of the death. Estimates of total COVID-19 mortality were constructed with use of the statistical model developed by the COVID-19 Excess Mortality Collaborators to predict the excess mortality rate for all locations between Jan 1, 2020, and Nov 14, 2021.16 To estimate total COVID-19 mortality, we predicted a counterfactual excess mortality rate due to COVID-19 in which the IDR was set to the maximum observed values among all locations. The predicted excess mortality rate from this counterfactual analysis, corrected for under-reporting, resulted from insufficient testing and changes in mortality driven by behaviours such as deferred health care during periods of lockdown. We used the ratio of this counterfactual excess mortality rate and the prediction for the same period as a proxy for the proportion of excess mortality that is total COVID-19 mortality. Subsequently, a scalar of reported COVID-19 deaths to total COVID-19 deaths can be derived (more details in appendix 1, section 9.4). We identified seroprevalence surveys through a search protocol that leveraged previous reviews,24,25 SeroTracker,26 and routine inclusion of national and subnational surveys undertaken by governmental organisations. Studies that focused on specific subsets of the population--either a specific subpopulation such as health-care workers or specific locations such as specific cities--were typically excluded as a result of not being representative. In total, we identified 2817 seroprevalence survey datapoints (of 6420 reviewed) for inclusion in this analysis.
Although most data streams for daily cases, deaths, and hospitalisations are indexed by date of report, some are indexed by date of event; in these instances, lags in

reporting create misleading trends in the most recent days of data. These trends are gradually corrected over time as reporting systems catch up but, to prevent this occurrence from influencing our models, we needed to evaluate each individual data source and determine an appropriate number of days to exclude in any iteration of the analyses.
Some hospital admissions data series only became available starting from weeks or months after the beginning of the COVID-19 pandemic--for example, the HHS database began in July, 2020. However, total cumulative hospitalisations are required to create our empirical estimate of IHR. In these instances, we leveraged information from the metrics that did have complete time coverage (cases and deaths) to impute the earlier portion of the admissions time series (appendix 1, section 4.2).
Seroprevalence survey adjustments Seroprevalence surveys were corrected for vaccination, because vaccination generates a positive anti-spike antibody test in most individuals who receive the vaccine.27 In locations where vaccination rates have increased over time, population levels of anti-spike antibodies will be elevated. To correct for this, we adjusted seroprevalence estimates downward on the basis of vaccination rates in adults in every location, accounting for vaccination of previously infected individuals (appendix 1, section 5.1).
Seroprevalence surveys provide an estimate of the number of individuals who have been infected with SARS-CoV-2 one or more times; these surveys do not detect repeat infections in a single individual. Because reinfection can be common in settings where escape variants such as beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are present,28-30 we had to adjust seroprevalence data to estimate the cumulative number of infections-- that is, to include both first and any subsequent infections. We used a level of cross-variant immunity of 30% to 70% between escape variants and ancestral variants and alpha (B.1.1.7), on the basis of an empirical analysis conducted by the COVID-19 Forecasting Team (unpublished). This estimate did not take into account that some individuals could have been infected more than once with ancestral variants.31 A detailed explanation of how we adjusted for escape variant prevalence is given in appendix 1 (section 5.2).
Lastly, seroprevalence surveys were corrected for waning sensitivity of antibody tests. We identified eight categories of antibody tests; for each of these, we used a reported curve of sensitivity over time.32-34 To implement the correction based on waning, we used initial estimates of the timing of infection based on reported deaths. We did not adjust for specificity, as reported specificity for all available commercial assays included in the analysis is over 95% and mostly over 98% (more details in appendix 1, sections 5.3 and 9.3).35

2354

www.thelancet.com Vol 399 June 25, 2022

Articles

Empirical estimates of the IDR, IHR, and IFR Using the adjusted seroprevalence data we have described, we created a dataset of 2817 empirical measurements of the IDR in which the numerator was the cumulative number of confirmed cases and the denominator was the number of cumulative infections and reinfections combined. We aligned cases and seroprevalence on the basis of individual record data suggesting that exposure to a laboratory-confirmed case was typically 10-13 days36 and exposure to seroconversion was 14-17 days.37-39 Figure 1A shows these empirical estimates of location-specific IDR over the course of the pandemic. For the purposes of visualising the data, the IDR data are time-localised to the average date of infection based on the model estimate and daily cases.
Using adjusted seroprevalence surveys matched to cumulative hospitalisations, we developed a dataset of 2580 empirical estimates of the IHR. Based on the same data and analysis used to determine the lag for cases,36 we used a 10-13-day lag for hospitalisations. Far fewer locations reported hospitalisations, so less information was available for this metric than for the IDR. We used 703 surveys that included age-specific seroprevalence data to estimate the IHR age pattern, and we then used indirect age standardisation to estimate the age-standardised IHR across locations and used those age-standardised estimates in the modelling of the IHR (more details on indirect standardisation methods in appendix 1, section 6.1). Figure 1B shows the universe of available age-standardised IHR over time. For the purposes of visualising the data, IHR data are timelocalised to the average date of admission.
Using the 718 seroprevalence surveys with age-specific detail, the COVID-19 Forecasting Team40 estimated the age pattern of the IFR. We used this age pattern to create a dataset of age-standardised IFR data using 2817 pairs of adjusted seroprevalence surveys and death data, assuming 22-28 days from exposure to death on the basis of analyses of patient-level data in the USA.41 Time indexing of IFR data was based on the average date of death for each observation. Figure 1C shows the relationship between age-standardised IFR and time.
Statistical models of the IDR, IHR, and IFR To generate estimates of daily infections from cases, hospitalisations, and deaths, we needed estimates of the IDR, IHR, and IFR by location for each day during the pandemic. We used a cascading implementation of a Bayesian regression framework42 to estimate each of these measures (more details in appendix 1, section 6.2). The cascading regression model allows for a flexible fit to the key covariates, including the option to specify them as splines, and borrows strength across locations. After parameterising the relationship of seroprevalence to cases, hospitalisations, and deaths through predictive models of IDR, IHR, and IFR, we

Infection-detection ratio

A

Central Europe, eastern Europe, and central Asia South Asia

High income

Southeast Asia, east Asia, and Oceania

Latin America and Caribbean

Sub-Saharan Africa

North Africa and Middle East

1·0

0·8

0·6

0·4

0·2

0
B
10-1

10-2

Age-standardised infection-hospitalisation ratio

Age-standardised infection-fatality ratio

C
10-2

10-3

May, 2020

July, 2020

September, 2020

November, 2020

January, 2021

March, 2021

Figure 1: Empirical measurements over time of infection-detection ratios (A), age-standardised infection- hospitalisation ratios (B), and age-standardised infection-fatality ratios (C) The y-axis for infection-hospitalisation ratios and infection-fatality ratios is shown in log base 10.

used local covariates and age structure to generate predictions of these ratios in both in-sample and out-ofsample locations based on our hierarchical cascade model. For the IDR model, the most spatially and temporally consistent predictive relationship was

www.thelancet.com Vol 399 June 25, 2022

2355

Articles

See Online for appendix 3

between testing per person and the IDR. To capture the rise in health system capacity to deliver testing, we used the observed maximum testing rate up to a given date as the covariate. Additionally, we included universal healthcare coverage, the Healthcare Access and Quality (HAQ) Index, and the proportion of the population older than 65 years as covariates that each submodel selected from in our ensemble. These covariates were estimated for all locations as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD; appendix 1, sections 6.3 and 9.6).43
Predictive covariates for IHR and IFR were primarily based on a list of underlying medical conditions identified by the US Centers for Disease Control and Prevention (CDC) as increasing the risk of severe illness from SARS-CoV-2 infection.44 We cross-referenced this list with a study of individuals admitted to hospital in the USA41 that evaluated the increased risk of in-hospital death to identify seven possible covariates, all of which were included in our models as age-standardised prevalence in the population (estimated as part of GBD): obesity, smoking, diabetes, cancer, chronic obstructive pulmonary disease, cardiovascular disease, and chronic kidney disease.43 Several of these covariates, most prominently obesity, were further supported by relationships in US claims45 and Brazil hospitalisations data.46 To this list, we also added universal health-care coverage and the HAQ Index. We then tested all possible combinations of these covariates and selected the top 100 most predictive combinations to use across submodels in our ensemble models of IHR and IFR (more details in appendix 1, section 9.6). We estimated age-standardised IHR and IFR using these covariates and then converted estimates back to all-age IHR and IFR to reflect population structure. We accounted for reductions in the IFR due to improved treatment over the course of the pandemic by including a spline on time in the regressions in addition to the ensemble covariates (more details on these models in appendix 1, sections 6.4, 6.5, and 9.6).
Vaccines and variants also affect the likelihood of severe disease and death, and thus influence both the IHR and the IFR. First, vaccination strategies that prioritise older age groups before younger ones can temporarily increase the relative proportion of infections that occur in younger individuals, thus lowering the population-level IFR and IHR for at least a period of time. Additionally, COVID-19 vaccines have been shown to confer higher levels of protection from severe disease and death than from mild infection, also serving to lower the overall IFR and IHR. The prevalence of variants with higher likelihood of severe disease and death can conversely increase these ratios,47 and the introduction of escape variants can increase them further by reducing vaccine efficacy. More information on how we accounted for these features can be found in appendix 1 (section 6.6).

Robust estimates of daily infections We then paired the estimates of our ratio models with data that were reported by local jurisdictions--accounting for reporting biases in cases through the testing covariate and in deaths through the total COVID-19 death scalars-- to estimate infections in a manner that was sensitive to local context, even in the absence of seroprevalence data. By dividing cases by the modelled IDR, hospitalisations by the modelled IHR, and deaths by the modelled IFR, we produced three daily infections time series (or two if only cases and deaths were reported for a given location). Estimates based on each input data type were shifted back in time by their respective lags, such that they were all indexed on date of infection. We then fit a time series spline model using all three data sources as inputs to triangulate a best estimate of daily infections. After deriving this mean estimate of daily infections, we sampled the residuals of the intermediate case-based, hospitalisation-based, and deaths-based infection estimates independently in each submodel and refit the infections curve to these data; this enabled us to more accurately reflect the volatility in reporting practices, such as for deaths, in our ensemble distribution of daily infections (more details in appendix 1, section 7).
Cumulative infections and cumulative proportion of the population infected at least once Daily infections, including reinfections, were summed to derive an estimate of cumulative infections. With this estimate of cumulative infections, we then returned to reported cases, reported hospitalisations, and total COVID-19 deaths to produce posterior estimates of cumulative IDR, IHR, and IFR. Where the reported data were not available, the posterior ratio estimate would be equal to the prediction from the ratio model. To estimate the proportion of individuals who were infected with SARS-CoV-2 at least once by Nov 14, 2021, we used the same assumptions already described. The crucial assumptions required were cross-variant immunity, the prevalence of escape variants, and the assumption that exposure to escape variants is independent of the probability of previous infection with ancestral variants.
Figures found in appendix 3 show cases, hospitali­sations (where available), deaths, IDR, IHR, IFR, daily infections, cumulative infections, and cumulative proportion of the population infected at least once for 399 locations.
Reffective estimation in the past Using daily infections, we directly estimated Reffective in the past by location and day, where Reffective at time t is:
Reffective(t)= ininfefcetcitoinons(st(+t))
The assumptions required for this estimation are the duration from infection to being infectious and the period of infectiousness, collectively represented as .

2356

www.thelancet.com Vol 399 June 25, 2022

Articles

A

17·5

Central Europe, eastern Europe, and central Asia

High income

Latin America and Caribbean

North Africa and Middle East

15·0

South Asia

Southeast Asia, east Asia, and Oceania

Sub-Saharan Africa

12·5

Daily global infections (in millions)

10·0

7·5

5·0

2·5

0
B
4·0

3·5

3·0

Cumulative global infections (in billions)

2·5

2·0

1·5

1·0

0·5

0 March,
2020

May, 2020

July,

September, November, January,

March,

May,

2020

2020

2020

2021

2021

2021

Figure 2: Daily (A) and cumulative (B) infections by super-region from Feb 4, 2020, to Nov 14, 2021

July,

September, November,

2021

2021

2021

We used ranges of 3-5 days for both assumptions to generate estimates of Reffective in the past. These estimates are useful for identifying the effect of different non-pharmaceutical interventions on transmission in different settings. An Reffective lower than 1·0 indicates that the epidemic is shrinking, whereas an Reffective higher than 1·0 indicates that the epidemic is growing.

We compared Reffective to an estimate of total immunity in the population of location l at time t (presented as weekly averages), where this value is calculated as:
total immunityl,t=1 (1 - prop.infectedl,t) (1 - prop.effectively vaccinatedl,t)

www.thelancet.com Vol 399 June 25, 2022

2357

Articles

Global Central Europe, eastern Europe, and central Asia Central Asia
Armenia Azerbaijan Georgia Kazakhstan Kyrgyzstan Mongolia Tajikistan Turkmenistan Uzbekistan Central Europe Albania Bosnia and Herzegovina Bulgaria Croatia Czechia Hungary Montenegro North Macedonia Poland Romania Serbia Slovakia Slovenia Eastern Europe Belarus

Cumulative total COVID-19 deaths
15100000 (11200000-20200000) 1510000 (1280000-1880000)
217000 (157000-317000)
15900 (11500-22700)
41500 (30000-59600)
11900 (11000-16400)
49800 (36000-69500)
18700 (13400-27600)
4540 (3590-5970)
10400 (5710-17900)
9750 (5190-16500)
54300 (38400-80000)
506000 (393000-681000)
14000 (10000-19900)
16300 (12000-22700)
61700 (48000-83000)
15900 (12200-20900)
38400 (31500-49300)
39100 (32100-51600)
3300 (2470-4670)
16200 (11800-22200)
153000 (116000-205000)
94900 (71600-133000)
28100 (20900-40300)
19300 (16000-23100)
5640 (4930-6670)
786000 (725000-881000)
66100 (47800-95400)

Cumulative total COVID-19 death rate (per 100000 population)
194·5 (144·5-261·6)
361·2 (305·4-449·7)
231·8 (168·1-338·5)
525·0 (379·6-753·1)
403·6 (291·7-579·4)
325·9 (299·4-448·3)
270·8 (195·7-377·9)
286·3 (205·3-421·8)
134·1 (106·0-176·2)
110·0 (60·2-188·5)
191·9 (102·2-324·3)
161·1 (114·0-237·6)
442·6 (344·0-596·5)
513·7 (367·4-731·2)
493·5 (364·4-688·8)
889·1 (692·8-1197·5)
374·5 (287·7-492·7)
360·7 (295·7-462·8)
404·5 (331·6-533·4)
532·1 (397·5-753·3)
753·1 (550·2-1033·6)
397·3 (303·0-534·6)
493·2 (372·1-691·9)
321·8 (239·1-460·2)
354·9 (293·7-424·2)
272·1 (237·5-321·4)
374·5 (345·1-419·5)
695·8 (503·1-1004·2)

Cumulative infections
3800000000 (3440000000-4080000000)
328000000 (206000000-390000000)
68900000 (40900000-95600000)
2940000 (1790000-3610000)
9560000 (4640000-12600000)
3460000 (1580000-4400000)
12200000 (6320000-20100000)
5570000 (4150000-7640000)
2190000 (1510000-2490000)
7650000 (5120000-9960000)
4100000 (2740000-5330000)
21300000 (7470000-33200000)
74600000 (54100000-92200000)
2780000 (1890000-3120000)
2870000 (2070000-3540000)
6020000 (3290000-7880000)
2570000 (2160000-3430000)
7980000 (5730000-9530000)
5620000 (3980000-7420000)
686000 (644000-731000)
2110000 (1500000-2440000)
20500000 (10300000-30000000)
13400000 (9130000-17900000)
6400000 (4450000-8410000)
2760000 (2060000-4250000)
936000 (634000-1550000)
184000000 (66200000-227000000)
6430000 (2520000-10700000)

Cumulative infection rate (per 100 population)
49·1 (44·4-52·7)
78·4 (49·3-93·2)
73·7 (43·7-102·2)
97·5 (59·4-119·7)
93·0 (45·2-122·7)
94·5 (43·0-120·0)
66·2 (34·3-109·2)
85·3 (63·6-116·9)
64·6 (44·5-73·6)
80·6 (53·9-104·9)
80·6 (53·9-104·9)
63·2 (22·2-98·5)
65·3 (47·4-80·7)
102·1 (69·5-114·8)
87·0 (62·8-107·1)
86·8 (47·4-113·7)
60·5 (50·8-80·8)
75·0 (53·8-89·5)
58·1 (41·2-76·7)
110·5 (103·8-117·9)
97·9 (69·9-113·6)
53·3 (26·7-77·9)
69·6 (47·5-93·0)
73·2 (50·9-96·2)
50·8 (37·9-78·2)
45·1 (30·6-74·8)
87·7 (31·5-108·1)
67·7 (26·6-112·9)

Cumulative percentage infected
43·9% (39·9-46·9)
67·7% (45·7-77·8)
64·5% (41·1-84·7)
81·4% (55·7-90·3)
77·4% (42·3-90·9)
79·4% (40·4-94·2)
58·6% (33·0-86·1)
76·1% (61·2-92·1)
58·2% (41·6-64·2)
69·9% (50·1-84·7)
70·0% (50·3-84·7)
56·8% (21·7-82·8)
59·5% (44·3-72·7)
86·9% (64·0-92·7)
76·7% (57·8-90·4)
74·3% (44·8-89·6)
55·5% (47·5-71·1)
70·1% (51·6-81·5)
53·6% (38·9-69·4)
89·4% (87·9-90·5)
84·2% (64·0-91·6)
50·6% (26·1-71·9)
62·1% (44·0-80·9)
64·5% (47·3-81·1)
47·9% (36·5-71·4)
42·2% (29·1-66·4)
73·6% (30·1-87·3)
59·4% (25·7-90·6)

Cumulative infection- detection ratio
6·9% (6·4-7·6)
10·1% (8·3-15·6)
6·2% (4·2-10·2)
11·8% (9·3-18·8)
6·5% (4·6-12·5)
26·6% (18·8-52·9)
9·8% (5·2-16·7)
3·4% (2·4-4·4)
30·7% (26·5-43·7)
1·2% (0·4-2·2)
4·3% (1·7-8·1)
1·0% (0·6-2·6)
18·1% (14·4-24·4)
7·3% (6·3-10·5)
9·7% (7·7-13·2)
12·1% (8·7-20·9)
23·3% (17·2-27·4)
26·4% (21·8-36·1)
19·4% (14·1-26·8)
22·8% (21·3-24·2)
10·3% (8·7-14·2)
18·1% (11·5-33·8)
13·7% (9·9-19·4)
20·0% (14·8-28·0)
41·9% (26·3-54·4)
48·8% (26·7-65·9)
9·2% (6·5-22·4)
11·9% (6·0-25·7)

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

1·2% (1·0-1·6)

0·4% (0·3-0·5)

2·0% (1·5-2·5)

0·5% (0·4-0·8)

1·0% (0·8-1·7)

0·4% (0·2-0·6)

1·7% (1·2-2·6)

0·6% (0·4-1·0)

1·2% (0·8-2·0)

0·5% (0·3-1·0)

1·8% (1·3-3·0)

0·4% (0·3-0·9)

1·2% (0·9-2·0)

0·5% (0·2-0·9)

0·9% (0·6-1·6)

0·4% (0·2-0·6)

0·8% (0·6-1·5)

0·2% (0·2-0·3)

0·7% (0·5-1·3)

0·2% (0·1-0·3)

1·1% (0·8-1·9)

0·3% (0·1-0·5)

0·8% (0·6-1·5)

0·3% (0·1-0·8)

1·7% (1·2-2·4)

0·8% (0·5-1·1)

1·4% (1·0-2·0)

0·5% (0·4-0·8)

1·7% (1·2-2·5)

0·6% (0·4-0·9)

2·0% (1·5-2·9)

1·2% (0·7-2·1)

2·2% (1·6-2·6)

0·7% (0·5-1·0)

1·9% (1·6-2·7)

0·5% (0·4-0·7)

2·0% (1·5-2·9)

0·8% (0·5-1·2)

1·4% (1·0-1·9)

0·5% (0·4-0·7)

1·4% (1·0-2·0)

0·8% (0·5-1·2)

1·4% (0·9-2·7)

0·9% (0·5-1·6)

1·8% (1·3-2·6)

0·8% (0·5-1·3)

1·7% (1·2-2·4)

0·5% (0·3-0·7)

1·8% (1·3-2·6)

0·8% (0·5-1·1)

1·9% (1·4-2·8)

0·7% (0·4-1·1)

2·5% (1·8-3·2)

0·5% (0·4-1·4)

2·8% (2·0-3·6)

1·3% (0·6-2·7)

(Table continues on next page)

2358

www.thelancet.com Vol 399 June 25, 2022

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Estonia

4520 (3750-5150)

Latvia

9340 (7250-11800)

Lithuania

15400 (12200-19000)

Moldova

12700 (9210-18500)

Russia

552000 (552000-552000)

Ukraine

126000 (92000-180000)

High income

2330000 (1990000-2770000)

Australasia

1920 (1920-1920)

Australia

1890 (1890-1890)

New Zealand

36 (36-36)

High-income Asia Pacific

102000 (79400-138000)

Brunei

125 (96-194)

Japan

97700 (75600-135000)

Singapore

585 (585-585)

South Korea

3260 (3110-4420)

High-income North America

1020000 (857000-1220000)

Canada

38700 (31400-46600)

Alberta

4880 (3520-6280)

British Columbia

4280 (3190-5470)

Manitoba

1930 (1330-3120)

New Brunswick

262 (183-353)

Newfoundland and Labrador

85 (48-121)

Northwest Territories

28 (21-37)

Nova Scotia

276 (179-371)

Nunavut

14 (10-17)

Ontario

13600 (10100-16900)

Quebec

12000 (11500-14300)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

344·4 (285·7-392·4)
487·8 (378·7-616·4)
551·9 (435·2-680·8)
344·0 (249·7-502·6)
376·4 (376·4-376·4)
286·1 (208·8-408·2)
214·9 (183·5-256·0)
6·6 (6·6-6·6)
7·7 (7·7-7·7)
0·8 (0·8-0·8)
54·3 (42·4-73·9)
28·5 (21·9-44·3)
76·5 (59·2-105·3)
10·3 (10·3-10·3)
6·1 (5·8-8·3)
278·7 (235·0-333·5)
106·0 (86·0-127·7)
114·8 (82·7-147·6)
87·0 (64·8-111·0)
145·3 (100·1-235·1)
34·9 (24·4-47·0)
17·0 (9·5-24·2)
65·4 (49·6-84·8)
29·3 (19·0-39·4)
36·4 (27·7-45·2)
95·7 (71·0-118·9)
145·6 (140·0-174·4)

425000 (326000-760000)
1050000 (530000-1900000)
1930000 (1110000-2870000)
3040000 (1700000-4070000)
139000000 (36800000-166000000)
32600000 (16800000-50200000)
239000000 (226000000-252000000)
356000 (328000-392000)
340000 (313000-375000)
16000 (13900-18200)
7890000 (6630000-9480000)
35400 (27400-50800)
6450000 (5080000-8020000)
408000 (355000-501000)
993000 (744000-1260000)
118000000 (109000000-125000000)
4620000 (3700000-5710000)
760000 (570000-1160000)
707000 (494000-952000)
505000 (178000-728000)
30700 (20400-54000)
9400 (6320-15500)
5010 (3650-7060)
23800 (17500-34300)
2130 (1630-2840)
1520000 (1060000-2070000)
849000 (630000-1150000)

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

32·4 (24·8-57·9)
55·1 (27·7-99·2)
69·2 (39·6-102·7)
82·5 (46·0-110·4)
94·5 (25·1-113·4)
73·9 (38·1-114·0)
22·1 (20·9-23·3)
1·2 (1·1-1·3)
1·4 (1·3-1·5)
0·4 (0·3-0·4)
4·2 (3·5-5·1)
8·1 (6·3-11·6)
5·0 (4·0-6·3)
7·2 (6·3-8·8)
1·9 (1·4-2·4)
32·3 (29·9-34·2)
12·7 (10·1-15·6)
17·9 (13·4-27·3)
14·4 (10·0-19·3)
38·0 (13·4-54·9)
4·1 (2·7-7·2)
1·9 (1·3-3·1)
11·6 (8·4-16·3)
2·5 (1·9-3·6)
5·6 (4·3-7·5)
10·7 (7·5-14·6)
10·3 (7·7-14·0)

30·9% (24·1-53·2)
49·8% (26·7-83·1)
61·1% (37·2-82·6)
73·1% (43·2-91·7)
78·2% (24·3-87·2)
64·4% (36·5-90·6)
21·3% (20·1-22·5)
1·2% (1·1-1·3)
1·4% (1·3-1·5)
0·3% (0·3-0·4)
4·2% (3·5-5·0)
7·8% (5·9-11·3)
5·0% (4·0-6·2)
7·1% (6·2-8·7)
1·8% (1·4-2·3)
30·9% (28·8-32·8)
12·4% (9·9-15·2)
17·4% (13·2-26·5)
14·1% (9·9-18·8)
36·1% (13·1-50·7)
3·6% (2·3-6·7)
1·6% (1·0-2·6)
8·1% (4·7-13·3)
2·5% (1·8-3·6)
4·7% (2·7-6·0)
10·6% (7·4-14·4)
10·2% (7·6-13·9)

53·9% (31·8-67·7)
26·6% (13·2-47·3)
25·8% (16·1-41·9)
12·6% (8·9-21·3)
8·1% (5·6-25·4)
12·1% (7·1-21·2)
44·6% (42·3-47·2)
57·4% (51·8-62·1)
57·6% (52·0-62·5)
53·7% (47·3-60·8)
31·1% (25·6-36·6)
43·3% (29·4-54·4)
27·1% (21·5-33·9)
64·0% (51·6-72·8)
44·6% (34·7-58·0)
42·3% (39·8-45·6)
38·9% (31·2-48·1)
45·4% (29·0-58·6)
31·6% (22·8-43·8)
14·9% (9·2-37·6)
27·7% (14·8-39·3)
22·9% (13·2-32·2)
42·0% (28·9-55·7)
35·5% (23·6-46·5)
32·2% (23·5-41·1)
41·7% (29·7-57·9)
54·0% (38·6-70·3)

3·1% (1·8-3·9)

1·2% (0·7-1·5)

3·0% (2·1-3·9)

1·2% (0·6-2·0)

2·8% (2·0-3·6)

0·9% (0·5-1·5)

2·4% (1·7-3·1)

0·5% (0·3-0·8)

2·5% (1·7-3·2)

0·5% (0·4-1·7)

2·8% (2·0-3·6)

0·5% (0·3-0·9)

3·3% (3·1-3·5)

1·0% (0·9-1·2)

2·5% (2·2-2·8)

0·6% (0·5-0·6)

2·6% (2·3-2·9)

0·6% (0·5-0·7)

1·5% (1·4-1·6)

0·3% (0·3-0·4)

4·1% (3·7-4·7)

1·3% (1·0-1·7)

1·7% (1·4-1·9)

0·4% (0·3-0·5)

4·5% (3·9-5·0)

1·5% (1·1-2·1)

2·4% (2·1-2·7)

0·2% (0·2-0·2)

2·6% (2·3-2·9)

0·4% (0·3-0·6)

3·4% (3·2-3·7)

0·9% (0·7-1·1)

1·8% (1·4-2·2)

0·9% (0·7-1·2)

2·2% (1·4-2·8)

0·7% (0·4-0·9)

1·8% (1·3-2·5)

0·7% (0·4-1·0)

1·1% (0·6-2·7)

0·5% (0·2-1·1)

1·4% (1·0-1·9)

1·0% (0·5-1·4)

1·5% (1·1-1·9)

1·2% (0·7-1·8)

1·5% (1·1-2·0)

0·6% (0·4-0·9)

1·6% (1·1-2·1)

1·3% (0·8-1·9)

1·5% (1·1-2·0)

0·7% (0·4-0·9)

2·1% (1·5-3·0)

0·9% (0·6-1·3)

1·5% (1·2-2·0)

1·5% (1·0-2·1)

(Table continues on next page)

www.thelancet.com Vol 399 June 25, 2022

2359

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Saskatchewan

1370 (1030-1790)

Yukon

22 (17-27)

USA

977000

(826000-1170000)

Alabama

24100 (19500-29600)

Alaska

1350 (1060-1650)

Arizona

26200 (22300-31000)

Arkansas

12400 (10300-14700)

California

98600 (81400-118000)

Colorado

9780 (8640-11500)

Connecticut

9240 (8790-10500)

Delaware

3130 (2690-3660)

Washington, DC

1190 (1190-1190)

Florida

77000 (64100-93900)

Georgia

38200 (31200-47400)

Hawaii

1050 (1040-1200)

Idaho

5120 (4130-6160)

Illinois

36800 (28900-46100)

Indiana

18200 (17100-20900)

Iowa

7270

(7210-7940)

Kansas

8220 (6690-9860)

Kentucky

16000 (13000-19400)

Louisiana

20000 (16400-24100)

Maine

1970 (1370-2580)

Maryland

16500 (13100-20600)

Massachusetts

19200 (19200-19200)

Michigan

26300 (24400-31500)

Minnesota

9150 (9130-9370)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

120·6 (90·2-157·5)
56·1 (42·7-68·0)
298·0 (251·9-356·8)
485·1 (390·9-594·0)
171·1 (134·0-209·6)
361·7 (307·5-427·6)
406·2 (335·4-480·7)
247·3 (204·2-296·0)
181·1 (160·0-213·6)
250·2 (238·0-285·4)
320·8 (276·2-375·5)
182·8 (182·8-182·8)
363·5 (302·7-443·5)
358·5 (292·6-443·9)
70·8 (69·9-80·4)
294·8 (237·9-355·0)
282·1 (221·5-353·5)
270·3 (254·2-311·2)
232·3 (230·3-253·7)
276·9 (225·3-332·0)
356·0 (289·5-430·6)
436·3 (356·4-525·4)
145·7 (101·5-190·6)
268·2 (212·9-335·1)
287·5 (287·5-287·5)
270·6 (250·9-324·3)
164·4 (164·1-168·3)

208000 (144000-304000)
5570 (4120-7780)
113000000 (105000000-120000000)
2070000 (1710000-2430000)
281000 (228000-364000)
2560000 (2020000-3080000)
1090000 (831000-1310000)
11000000 (8960000-13200000)
1670000 (1300000-2140000)
814000 (659000-999000)
268000 (224000-327000)
154000 (120000-191000)
9200000 (7830000-10700000)
4250000 (3540000-5070000)
149000 (119000-207000)
773000 (579000-1010000)
4960000 (4220000-5760000)
2140000 (1610000-2760000)
1340000 (1050000-1660000)
1030000 (797000-1300000)
1710000 (1350000-2170000)
1720000 (1380000-2040000)
209000 (158000-308000)
1590000 (1210000-2040000)
1420000 (1240000-1760000)
3330000 (2840000-3890000)
1820000 (1450000-2280000)

18·3 (12·7-26·7)
14·1 (10·4-19·7)
34·5 (32·0-36·6)
41·5 (34·3-48·9)
35·6 (29·0-46·2)
35·3 (27·9-42·6)
35·7 (27·2-42·7)
27·5 (22·5-33·2)
30·9 (24·1-39·6)
22·0 (17·8-27·1)
27·5 (22·9-33·5)
23·7 (18·4-29·4)
43·5 (37·0-50·5)
39·8 (33·2-47·6)
10·0 (8·0-13·9)
44·5 (33·4-58·4)
38·0 (32·3-44·2)
31·9 (24·0-41·1)
42·7 (33·5-52·9)
34·7 (26·8-43·8)
37·9 (30·1-48·2)
37·5 (30·1-44·4)
15·4 (11·7-22·7)
25·9 (19·8-33·3)
21·3 (18·6-26·4)
34·2 (29·3-40·0)
32·7 (26·0-41·0)

17·5% (12·1-25·1)
6·2% (1·7-16·1)
33·0% (30·8-35·1)
39·3% (32·7-45·3)
33·6% (27·6-42·6)
33·8% (27·0-40·8)
34·1% (26·2-40·5)
26·7% (22·0-32·3)
29·6% (23·4-37·4)
21·6% (17·6-26·5)
26·6% (22·2-32·3)
23·2% (18·0-28·5)
40·8% (35·1-47·4)
37·8% (32·2-44·4)
9·8% (7·8-13·6)
41·7% (32·0-54·0)
36·5% (31·2-42·4)
30·6% (23·5-39·1)
40·6% (32·3-49·4)
33·3% (26·0-41·9)
35·9% (29·0-44·9)
35·9% (29·1-41·4)
15·0% (11·5-21·9)
25·2% (19·4-32·1)
20·8% (18·2-25·8)
32·8% (28·4-37·7)
31·3% (25·2-39·2)

40·2% (26·6-56·0)
27·0% (18·8-35·6)
42·4% (40·0-45·7)
41·2% (34·7-49·5)
53·9% (41·1-65·6)
49·7% (40·8-62·2)
48·8% (40·2-63·3)
46·6% (38·2-56·5)
50·1% (38·3-63·3)
52·0% (41·8-63·3)
57·4% (46·5-68·2)
43·7% (34·9-55·5)
40·8% (34·8-47·6)
39·4% (32·7-46·8)
59·8% (42·0-73·1)
40·4% (30·2-52·8)
36·3% (31·1-42·5)
52·0% (39·3-67·6)
39·5% (31·5-49·7)
45·5% (35·5-57·8)
46·3% (36·0-57·5)
45·1% (37·7-55·7)
58·7% (38·4-74·9)
37·2% (28·4-48·0)
64·5% (51·6-73·2)
44·2% (37·6-51·6)
49·9% (39·3-61·5)

1·6% (1·1-2·1)

0·7% (0·4-1·0)

1·2% (0·9-1·7)

0·6% (0·4-0·9)

3·5% (3·3-3·8)

0·9% (0·7-1·1)

4·1% (3·4-4·9)

1·2% (0·9-1·5)

1·9% (1·4-2·3)

0·5% (0·4-0·7)

4·0% (3·3-5·0)

1·1% (0·9-1·4)

4·2% (3·4-5·4)

1·2% (0·9-1·5)

3·3% (2·7-4·0)

0·9% (0·7-1·2)

3·6% (2·7-4·5)

0·7% (0·5-0·8)

4·1% (3·3-5·0)

1·2% (0·9-1·5)

4·2% (3·4-5·0)

1·2% (0·9-1·5)

6·0% (4·8-7·6)

0·8% (0·6-1·0)

3·9% (3·3-4·5)

0·9% (0·7-1·1)

4·3% (3·6-5·1)

0·9% (0·7-1·2)

4·9% (3·5-6·0)

0·7% (0·5-0·9)

2·2% (1·7-2·9)

0·7% (0·5-1·0)

2·6% (2·2-3·1)

0·8% (0·6-1·0)

4·0% (3·1-5·3)

0·9% (0·7-1·2)

2·5% (2·0-3·2)

0·6% (0·5-0·7)

3·4% (2·7-4·4)

0·8% (0·6-1·1)

6·5% (5·1-8·1)

1·0% (0·7-1·3)

4·6% (3·8-5·7)

1·2% (0·9-1·6)

2·9% (1·9-3·7)

1·1% (0·6-1·6)

4·0% (3·1-5·2)

1·1% (0·8-1·4)

3·6% (2·9-4·1)

1·4% (1·1-1·6)

3·4% (2·9-4·0)

0·9% (0·7-1·1)

2·4% (1·9-3·0)

0·5% (0·4-0·7)

(Table continues on next page)

2360

www.thelancet.com Vol 399 June 25, 2022

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Mississippi

16000 (12700-19900)

Missouri

18600 (15100-22500)

Montana

2960 (2590-3550)

Nebraska

3870 (3020-4740)

Nevada

8750 (7820-10300)

New Hampshire

2700 (2200-3190)

New Jersey

31000 (28100-38100)

New Mexico

7640 (6170-9100)

New York

68800 (56800-84200)

North Carolina

29300 (24000-35300)

North Dakota

1850 (1850-1850)

Ohio

35800

(28500-45800)

Oklahoma

15900 (12900-19000)

Oregon

8640 (6780-10200)

Pennsylvania

34500 (32300-41400)

Rhode Island

2880 (2880-2880)

South Carolina

20900 (17900-25000)

South Dakota

2340 (2270-2670)

Tennessee

22000 (18500-26100)

Texas

98400 (78600-124000)

Utah

3940

(3360-4680)

Vermont

1650 (1210-2030)

Virginia

21100 (18100-24400)

Washington

11200 (9010-13800)

West Virginia

7570 (6260-8590)

Wisconsin

10300 (9670-12000)

Wyoming

1680 (1330-2030)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

531·6 (424·3-662·8)
298·2 (242·6-360·0)
284·6 (248·7-341·4)
202·4 (157·8-247·4)
272·1 (243·1-320·1)
199·3 (162·4-236·1)
343·1 (311·0-422·0)
349·8 (282·3-416·3)
347·7 (286·8-425·4)
276·6 (227·1-333·7)
260·8 (260·8-260·8)
309·6 (246·5-395·3)
403·1 (327·4-481·9)
214·3 (168·3-253·5)
265·7 (248·6-318·7)
276·0 (276·0-276·0)
414·9 (354·4-496·5)
270·4 (262·8-308·7)
327·3 (275·7-388·4)
346·2 (276·6-436·6)
125·3 (106·8-148·5)
263·3 (193·5-323·2)
242·4 (207·6-280·3)
152·8 (123·4-188·6)
407·0 (336·7-461·6)
174·4 (164·4-204·2)
275·8 (217·4-333·2)

1250000 (1030000-1460000)
2280000 (1870000-2860000)
408000 (300000-545000)
819000 (630000-994000)
1320000 (1090000-1530000)
260000 (211000-338000)
3130000 (2610000-3660000)
666000 (535000-824000)
6550000 (5760000-7660000)
3450000 (2730000-4160000)
280000 (219000-377000)
4890000 (3800000-6040000)
1550000 (1130000-2030000)
814000 (538000-1230000)
3990000 (3270000-4900000)
273000 (249000-322000)
1890000 (1540000-2290000)
366000 (267000-505000)
2730000 (2230000-3340000)
13000000 (10700000-15200000)
1370000 (1120000-1740000)
73700 (65100-105000)
1850000 (1380000-2520000)
1320000 (1040000-1810000)
580000 (405000-818000)
2300000 (1820000-2800000)
291000 (205000-402000)

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

41·5 (34·2-48·7)
36·6 (29·9-45·8)
39·2 (28·9-52·4)
42·8 (32·9-51·9)
41·0 (34·0-47·6)
19·2 (15·6-25·0)
34·6 (28·8-40·5)
30·5 (24·5-37·7)
33·1 (29·1-38·7)
32·6 (25·7-39·3)
39·5 (30·9-53·3)
42·3 (32·8-52·1)
39·3 (28·7-51·4)
20·2 (13·3-30·6)
30·7 (25·2-37·7)
26·2 (23·8-30·8)
37·5 (30·6-45·4)
42·3 (30·8-58·4)
40·5 (33·1-49·7)
45·7 (37·6-53·6)
43·7 (35·5-55·4)
11·7 (10·4-16·7)
21·3 (15·8-29·0)
18·1 (14·3-24·8)
31·2 (21·8-44·0)
39·0 (31·0-47·7)
47·7 (33·5-65·8)

39·4% (32·8-45·5)
35·0% (28·9-43·2)
36·9% (27·3-48·4)
40·6% (31·5-48·2)
38·8% (32·8-45·0)
18·7% (15·3-24·0)
33·7% (28·2-39·1)
29·3% (23·8-35·9)
32·3% (28·3-37·7)
31·2% (24·8-37·1)
37·4% (29·5-49·5)
39·9% (31·3-48·5)
37·3% (27·9-48·5)
19·6% (13·1-29·1)
29·7% (24·6-36·3)
25·5% (23·3-29·9)
35·6% (29·5-42·6)
40·3% (29·7-54·8)
38·5% (31·9-46·6)
43·0% (35·4-50·3)
41·0% (34·0-50·4)
11·4% (9·7-16·2)
20·8% (15·5-27·9)
17·6% (14·0-23·8)
29·8% (21·1-41·4)
37·2% (29·9-45·3)
44·0% (31·8-61·1)

41·5% (35·0-49·9)
40·1% (31·6-48·4)
47·8% (34·8-63·3)
37·9% (30·7-48·5)
34·9% (29·8-41·7)
61·2% (46·7-74·0)
40·0% (33·9-47·6)
47·2% (37·6-57·8)
41·4% (35·2-47·0)
44·8% (36·6-55·9)
58·6% (42·4-73·1)
34·6% (27·7-44·0)
43·8% (32·7-58·5)
50·6% (31·6-72·2)
43·2% (34·9-52·1)
69·5% (58·9-76·2)
48·8% (40·0-59·3)
46·2% (32·6-61·5)
48·6% (39·2-58·9)
33·7% (28·5-40·6)
43·7% (33·8-53·0)
66·9% (46·8-74·4)
53·1% (38·3-69·8)
59·7% (42·7-74·0)
52·2% (35·6-72·0)
42·7% (34·4-53·2)
39·1% (27·5-54·0)

3·3% (2·8-4·0)

1·3% (1·0-1·6)

3·3% (2·6-4·0)

0·8% (0·6-1·1)

5·0% (3·6-6·6)

0·8% (0·6-1·1)

2·3% (1·9-3·0)

0·5% (0·4-0·7)

3·3% (2·8-4·0)

0·7% (0·6-0·9)

3·0% (2·3-3·6)

1·1% (0·8-1·5)

3·8% (3·2-4·5)

1·0% (0·8-1·3)

3·7% (3·0-4·5)

1·2% (0·9-1·6)

4·0% (3·4-4·6)

1·1% (0·9-1·4)

2·8% (2·3-3·4)

0·9% (0·7-1·2)

3·3% (2·4-4·1)

0·7% (0·5-0·9)

3·0% (2·4-3·8)

0·8% (0·6-1·1)

5·2% (3·9-7·0)

1·1% (0·8-1·5)

2·8% (1·7-4·0)

1·2% (0·7-1·9)

3·9% (3·1-4·6)

0·9% (0·7-1·1)

2·5% (2·1-2·7)

1·1% (0·9-1·2)

3·2% (2·6-3·9)

1·1% (0·9-1·5)

3·2% (2·2-4·2)

0·7% (0·5-0·9)

3·2% (2·6-3·8)

0·9% (0·7-1·1)

3·3% (2·8-3·9)

0·8% (0·6-1·1)

2·0% (1·5-2·4)

0·3% (0·2-0·4)

3·0% (2·1-3·3)

2·4% (1·7-3·1)

3·7% (2·6-4·8)

1·2% (0·8-1·7)

3·2% (2·3-4·0)

0·9% (0·6-1·2)

3·9% (2·6-5·3)

1·5% (0·9-2·1)

3·5% (2·8-4·3)

0·5% (0·4-0·6)

2·9% (2·0-4·0)

0·7% (0·4-0·9)

(Table continues on next page)

www.thelancet.com Vol 399 June 25, 2022

2361

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Southern Latin America

176000 (161000-235000)

Argentina

129000 (116000-184000)

Chile

38000

(37900-37900)

Uruguay

8840 (6720-12800)

Western Europe

1030000 (888000-1210000)

Andorra

276 (223-356)

Austria

14700 (12300-16600)

Belgium

28300 (26400-34000)

Cyprus

732 (592-1010)

Denmark

8600 (7250-9790)

Finland

6170 (4680-7630)

France

136000 (115000-165000)

Germany

160000 (129000-199000)

Baden-Württemberg

19600

(14900-25400)

Bavaria

26000 (19800-33300)

Berlin

7010 (5370-9110)

Brandenburg

5490 (4460-6720)

Bremen

1120 (848-1410)

Hamburg

3190 (2490-4170)

Hesse

12700 (10000-16100)

Lower Saxony

11500 (8900-13800)

MecklenburgVorpommern

2630 (1900-3330)

North RhineWestphalia

34400 (26800-44000)

Rhineland-Palatinate

6860

(5230-8620)

Saarland

1770 (1340-2240)

Saxony

13200 (11100-16800)

Saxony-Anhalt

4960 (4080-6060)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

263·3 (240·8-351·5)
285·8 (257·3-407·9)
208·7 (208·5-208·5)
257·4 (195·7-372·0)
237·0 (203·5-277·0)
331·8 (268·9-428·5)
164·6 (137·5-185·7)
248·1 (231·6-297·6)
55·7 (45·1-77·0)
148·2 (125·0-168·7)
111·5 (84·5-137·9)
205·0 (173·7-249·5)
188·6 (151·6-234·8)
174·5 (132·1-225·6)
196·0 (148·9-251·1)
192·7 (147·7-250·5)
213·7 (173·8-261·7)
161·4 (122·2-203·8)
173·0 (134·7-225·6)
198·5 (157·3-252·5)
140·1 (108·6-168·4)
158·2 (113·9-199·8)
186·4 (145·1-238·2)
163·8 (125·0-205·8)
172·1 (130·2-218·0)
312·3 (263·3-399·0)
213·8 (175·9-261·1)

17300000 (13000000-24000000)
12600000 (8920000-18500000)
3940000 (3090000-4870000)
788000 (626000-961000)
96000000 (88100000-105000000)
40400 (28200-52000)
2040000 (1730000-2660000)
3820000 (3080000-4680000)
186000 (179000-198000)
799000 (701000-936000)
484000 (413000-589000)
15800000 (12300000-23300000)
12400000 (11200000-13800000)
1640000 (1370000-1970000)
2240000 (1810000-2730000)
591000 (514000-667000)
387000 (334000-442000)
91000 (79700-107000)
240000 (203000-286000)
926000 (825000-1070000)
769000 (610000-872000)
173000 (150000-204000)
2790000 (2510000-3150000)
468000 (382000-581000)
127000 (108000-151000)
983000 (794000-1150000)
341000 (302000-388000)

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

25·9 (19·5-36·0)
27·9 (19·8-41·0)
21·7 (17·0-26·8)
22·9 (18·2-28·0)
22·0 (20·2-24·2)
48·6 (33·9-62·6)
22·9 (19·4-29·9)
33·4 (27·0-41·0)
14·2 (13·6-15·1)
13·8 (12·1-16·1)
8·7 (7·5-10·6)
23·9 (18·6-35·2)
14·6 (13·2-16·3)
14·5 (12·2-17·6)
16·9 (13·6-20·6)
16·3 (14·1-18·3)
15·1 (13·0-17·2)
13·1 (11·5-15·4)
13·0 (11·0-15·5)
14·5 (12·9-16·8)
9·4 (7·4-10·7)
10·4 (9·0-12·2)
15·1 (13·6-17·1)
11·2 (9·1-13·9)
12·4 (10·5-14·6)
23·3 (18·8-27·4)
14·7 (13·0-16·7)

25·1% (19·2-34·0)
27·0% (19·6-38·4)
21·1% (16·6-25·8)
22·3% (17·9-27·1)
21·4% (19·6-23·5)
46·4% (32·7-59·1)
22·2% (18·9-28·7)
32·0% (26·1-38·9)
13·9% (13·3-14·8)
13·5% (11·9-15·9)
8·6% (7·3-10·5)
23·3% (18·1-33·8)
14·4% (12·9-16·0)
14·2% (11·9-17·2)
16·5% (13·4-19·9)
15·9% (13·9-17·9)
14·8% (12·8-16·8)
12·9% (11·3-15·2)
12·8% (10·9-15·2)
14·3% (12·8-16·4)
9·3% (7·4-10·6)
10·2% (8·9-12·1)
14·9% (13·4-16·8)
11·0% (9·0-13·6)
12·1% (10·3-14·4)
22·6% (18·4-26·5)
14·4% (12·8-16·4)

44·1% (31·1-57·4)
43·5% (28·7-59·6)
45·1% (35·9-56·8)
51·5% (41·5-63·7)
48·9% (44·3-53·1)
42·0% (32·0-59·2)
55·2% (41·7-64·1)
44·6% (35·6-54·6)
70·9% (66·4-73·8)
59·0% (49·8-66·3)
38·1% (31·2-44·0)
49·0% (32·5-61·5)
45·0% (40·2-49·7)
48·6% (39·9-57·9)
48·5% (39·1-58·9)
45·0% (39·6-51·8)
42·9% (37·3-49·2)
42·7% (36·0-48·6)
46·7% (38·6-54·9)
43·5% (37·4-48·7)
47·7% (41·6-59·7)
38·6% (32·5-44·1)
40·9% (36·2-45·4)
48·2% (38·8-58·9)
46·3% (39·1-54·3)
46·6% (39·4-56·9)
42·7% (37·3-48·0)

2·5% (1·8-3·3)

1·0% (0·8-1·4)

1·9% (1·3-2·6)

1·1% (0·7-1·5)

4·1% (3·3-5·2)

1·0% (0·8-1·3)

4·1% (3·2-5·3)

1·1% (0·9-1·5)

3·3% (3·0-3·5)

1·1% (1·0-1·4)

3·2% (2·9-3·5)

0·7% (0·5-1·1)

3·6% (3·1-4·1)

0·8% (0·6-1·0)

2·4% (1·9-2·9)

0·8% (0·6-1·0)

3·2% (2·6-3·7)

0·4% (0·3-0·6)

2·5% (2·1-2·9)

1·2% (0·9-1·4)

3·5% (3·0-4·1)

1·5% (1·2-1·8)

3·7% (2·5-4·7)

0·9% (0·6-1·3)

3·0% (2·7-3·3)

1·4% (1·1-1·7)

2·8% (2·3-3·3)

1·3% (1·0-1·9)

2·5% (2·0-3·0)

1·3% (1·0-1·7)

3·0% (2·6-3·4)

1·2% (0·9-1·6)

2·8% (2·4-3·2)

1·5% (1·3-1·9)

3·3% (2·8-3·7)

1·3% (1·0-1·7)

2·6% (2·1-3·0)

1·4% (1·1-1·8)

3·3% (2·8-3·6)

1·4% (1·2-1·8)

2·5% (2·2-3·1)

1·6% (1·2-2·1)

3·5% (3·0-4·0)

1·7% (1·2-2·1)

3·9% (3·5-4·4)

1·3% (1·0-1·7)

2·6% (2·1-3·2)

1·5% (1·2-2·0)

2·3% (1·9-2·7)

1·5% (1·1-2·0)

2·7% (2·2-3·2)

1·5% (1·1-1·9)

3·2% (2·8-3·6)

1·6% (1·3-2·0)

(Table continues on next page)

2362

www.thelancet.com Vol 399 June 25, 2022

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Schleswig-Holstein

3730 (2870-4660)

Thuringia

6010 (5100-7600)

Greece

19100 (16800-22600)

Iceland

35 (35-35)

Ireland

5570 (5570-5570)

Israel

8670

(8130-9870)

Italy

227000

(182000-278000)

Abruzzo

4020 (3160-4960)

Basilicata

1500 (1130-1860)

Calabria

5580 (4060-7240)

Campania

16100 (12500-19600)

Emilia-Romagna

17400 (14200-21100)

Friuli-Venezia Giulia

4360

(3890-5160)

Lazio

16100

(13300-19300)

Liguria

8660 (7190-10800)

Lombardia

52200 (41200-66400)

Marche

6390 (5000-8000)

Molise

1680 (1360-2110)

Piemonte

24300 (20000-29200)

Prov autonoma di Bolzano

1430 (1210-1840)

Prov autonoma di Trento

1600 (1380-1930)

Puglia

15600 (11900-19300)

Sardegna

4060 (3110-5190)

Sicilia

16500 (12800-20600)

Toscana

11200 (9330-13700)

Umbria

2860 (2290-3550)

Valle d'Aosta

631 (499-767)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

126·2 (97·1-157·9)
267·9 (227·2-338·7)
184·5 (162·1-218·9)
10·1 (10·1-10·1)
113·5 (113·5-113·5)
93·2 (87·3-106·1)
375·9 (301·6-460·3)
306·3 (240·5-377·9)
266·3 (201·3-331·0)
288·7 (210·1-374·2)
278·3 (217·0-340·0)
383·9 (314·5-465·5)
359·0 (320·6-425·1)
281·4 (232·8-338·1)
559·3 (463·9-700·3)
522·1 (412·1-664·4)
409·5 (320·2-512·7)
552·1 (445·5-694·3)
555·1 (456·4-666·4)
271·1 (229·9-348·1)
292·4 (252·2-353·4)
384·5 (293·7-477·6)
249·5 (191·3-319·0)
329·1 (254·1-410·3)
300·2 (249·3-365·6)
314·8 (251·9-391·0)
494·4 (391·5-601·6)

222000 (189000-259000)
442000 (386000-524000)
1600000 (1430000-1790000)
28100 (25000-33300)
1130000 (863000-1590000)
2330000 (2090000-2680000)
12000000 (9360000-17700000)
198000 (151000-359000)
79300 (57500-121000)
337000 (241000-537000)
1010000 (734000-1630000)
955000 (751000-1420000)
240000 (182000-466000)
843000 (587000-1630000)
287000 (204000-428000)
2650000 (2020000-3810000)
331000 (255000-501000)
52500 (33100-83300)
991000 (677000-1720000)
161000 (123000-281000)
113000 (84600-182000)
811000 (560000-1260000)
211000 (155000-334000)
849000 (589000-1320000)
656000 (478000-1190000)
142000 (105000-232000)
33500 (25000-53700)

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

7·5 (6·4-8·8)
19·7 (17·2-23·4)
15·5 (13·9-17·3)
8·2 (7·3-9·6)
23·0 (17·6-32·4)
25·0 (22·4-28·8)
19·8 (15·5-29·4)
15·1 (11·5-27·4)
14·1 (10·2-21·6)
17·4 (12·5-27·8)
17·5 (12·7-28·3)
21·1 (16·6-31·4)
19·8 (15·0-38·4)
14·8 (10·3-28·4)
18·6 (13·2-27·6)
26·5 (20·2-38·1)
21·2 (16·3-32·1)
17·2 (10·9-27·4)
22·6 (15·4-39·2)
30·6 (23·4-53·3)
20·6 (15·4-33·2)
20·0 (13·8-31·2)
13·0 (9·5-20·5)
16·9 (11·7-26·3)
17·5 (12·8-31·8)
15·6 (11·6-25·6)
26·2 (19·6-42·1)

7·4% (6·3-8·7)
19·2% (16·8-22·5)
15·2% (13·6-16·9)
7·9% (7·0-9·4)
22·3% (17·1-31·1)
24·3% (21·8-27·7)
19·6% (15·4-28·6)
14·9% (11·4-26·8)
13·9% (10·1-21·2)
17·2% (12·4-27·1)
17·3% (12·6-27·6)
20·8% (16·4-30·6)
19·4% (14·8-37·3)
14·6% (10·2-27·7)
18·3% (13·1-27·0)
26·3% (20·1-37·6)
21·0% (16·2-31·4)
16·9% (10·7-27·1)
22·4% (15·3-38·6)
29·7% (22·9-50·7)
20·4% (15·3-32·7)
19·9% (13·8-30·6)
12·9% (9·5-20·1)
16·6% (11·6-25·6)
17·3% (12·7-30·9)
15·5% (11·5-25·1)
25·7% (19·3-41·5)

42·5% (36·3-49·4)
45·0% (38·2-51·3)
56·9% (50·8-63·9)
62·0% (52·3-69·0)
49·6% (34·4-63·9)
57·7% (49·9-64·1)
43·0% (28·2-53·2)
46·1% (24·2-57·6)
41·1% (25·9-54·5)
28·5% (17·1-38·1)
50·3% (29·8-66·2)
48·8% (31·8-59·9)
56·5% (27·6-70·8)
52·6% (25·8-71·5)
43·9% (28·3-59·0)
36·0% (24·3-45·7)
38·1% (24·5-47·8)
30·7% (18·1-45·5)
42·1% (23·0-58·7)
56·3% (30·6-69·8)
47·2% (28·3-60·7)
36·0% (22·1-49·7)
39·9% (24·2-52·2)
39·8% (24·3-54·5)
48·6% (25·2-62·5)
49·4% (29·0-63·7)
40·4% (24·0-51·6)

3·2% (2·7-3·7)

1·8% (1·4-2·3)

3·3% (2·8-3·8)

1·5% (1·2-2·0)

4·1% (3·5-4·8)

1·4% (1·1-1·6)

2·8% (2·3-3·2)

0·1% (0·1-0·1)

1·3% (0·9-1·6)

0·5% (0·4-0·7)

2·5% (2·2-2·8)

0·4% (0·3-0·4)

3·9% (3·4-4·4)

2·0% (1·3-2·7)

4·2% (3·6-4·7)

2·2% (1·2-3·0)

3·9% (3·3-4·4)

2·0% (1·2-2·9)

3·5% (2·9-4·1)

1·8% (1·1-2·6)

3·5% (2·9-4·0)

1·7% (1·0-2·4)

4·2% (3·7-4·7)

1·9% (1·3-2·5)

4·4% (3·9-4·9)

2·0% (1·0-2·7)

4·0% (3·6-4·5)

2·1% (1·0-3·0)

4·7% (4·1-5·2)

3·2% (1·9-4·6)

3·9% (3·4-4·4)

2·0% (1·3-2·9)

4·2% (3·6-4·8)

2·0% (1·3-2·9)

4·1% (3·5-4·6)

3·4% (2·1-5·5)

4·1% (3·6-4·5)

2·6% (1·5-3·6)

3·5% (3·0-3·9)

1·0% (0·5-1·3)

3·8% (3·4-4·3)

1·5% (0·9-2·1)

3·8% (3·2-4·4)

2·0% (1·2-3·0)

3·9% (3·3-4·5)

2·0% (1·2-2·9)

3·6% (3·0-4·1)

2·1% (1·2-3·0)

3·9% (3·4-4·3)

1·9% (0·9-2·7)

4·2% (3·6-4·7)

2·1% (1·2-3·0)

4·0% (3·5-4·5)

2·0% (1·1-2·8)

(Table continues on next page)

www.thelancet.com Vol 399 June 25, 2022

2363

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Veneto

14600 (12000-17600)

Luxembourg

974 (854-1190)

Malta

672 (475-887)

Monaco

47 (37-55)

Netherlands

38000 (32400-43100)

Norway

973 (968-984)

Portugal

35800 (29600-42200)

San Marino

98 (91-127)

Spain

145000 (120000-174000)

Andalusia

20900 (16900-27100)

Aragon

5320 (4370-6640)

Asturias

3010 (2390-3670)

Balearic Islands

2530 (1870-3220)

Basque Country

6830 (5700-8310)

Canary Islands

2930 (2220-3880)

Cantabria

1260 (967-1480)

Castile and León

8850 (7140-11200)

Castilla-La Mancha

8180 (7170-9610)

Catalonia

32000 (27100-39000)

Ceuta

224 (181-271)

Community of Madrid

24500 (20700-31300)

Extremadura

3120 (2490-3680)

Galicia

5120 (4090-6120)

La Rioja

1120 (916-1440)

Melilla

254 (188-334)

Murcia

3190 (2550-3830)

Navarre

2020 (1650-2520)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

295·3 (243·2-355·8)
157·5 (138·0-192·9)
153·1 (108·0-202·0)
125·0 (97·9-146·2)
221·6 (188·8-251·0)
18·2 (18·1-18·4)
336·5 (278·3-396·6)
295·7 (274·8-382·6)
314·3 (260·6-379·1)
254·2 (204·7-328·8)
412·0 (338·6-514·2)
300·9 (238·5-367·1)
224·7 (166·6-286·0)
316·3 (264·0-384·8)
138·9 (105·4-184·2)
222·4 (170·1-261·1)
376·8 (304·2-475·2)
411·4 (360·4-482·9)
426·0 (360·8-519·7)
269·8 (218·0-326·0)
375·1 (318·1-479·2)
298·4 (238·8-352·4)
193·8 (154·7-231·7)
360·1 (295·6-464·1)
300·1 (221·5-394·5)
218·4 (174·7-261·9)
315·1 (257·3-394·1)

1010000 (755000-1930000)
153000 (134000-185000)
68500 (59900-81100)
6570 (5810-7330)
4840000 (4120000-6600000)
614000 (356000-1630000)
2370000 (1890000-3080000)
14300 (11200-16800)
11800000 (10400000-14200000)
2150000 (1550000-4270000)
381000 (305000-486000)
176000 (127000-302000)
217000 (149000-388000)
477000 (431000-542000)
390000 (239000-812000)
104000 (79900-155000)
644000 (576000-801000)
552000 (463000-730000)
2250000 (1770000-3080000)
18100 (14500-23000)
2270000 (1910000-2750000)
213000 (169000-325000)
334000 (283000-408000)
66200 (58500-86400)
37100 (21700-68000)
275000 (209000-490000)
199000 (179000-238000)

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

20·4 (15·3-39·1)
24·7 (21·7-29·8)
15·6 (13·6-18·5)
17·5 (15·5-19·5)
28·2 (24·0-38·4)
11·5 (6·6-30·5)
22·3 (17·8-28·9)
43·1 (33·9-50·6)
25·5 (22·6-30·8)
26·1 (18·9-51·8)
29·5 (23·6-37·6)
17·6 (12·7-30·2)
19·3 (13·3-34·5)
22·1 (19·9-25·1)
18·5 (11·3-38·5)
18·4 (14·1-27·3)
27·4 (24·5-34·1)
27·7 (23·3-36·7)
30·0 (23·6-41·0)
21·8 (17·4-27·8)
34·8 (29·2-42·2)
20·4 (16·2-31·1)
12·6 (10·7-15·4)
21·3 (18·9-27·9)
43·9 (25·6-80·3)
18·8 (14·3-33·5)
31·1 (27·9-37·2)

20·0% (15·1-37·6)
24·1% (21·2-29·1)
14·9% (13·0-17·5)
12·8% (11·2-14·4)
27·1% (23·2-36·9)
11·2% (6·6-28·9)
21·9% (17·5-28·2)
40·7% (32·2-47·7)
24·9% (22·0-30·0)
25·6% (18·6-49·1)
28·8% (23·3-36·4)
17·3% (12·6-29·4)
18·8% (13·0-32·6)
21·6% (19·5-24·6)
18·1% (11·2-36·4)
18·1% (13·9-26·8)
27·0% (24·3-33·6)
27·3% (23·0-35·9)
29·0% (22·9-39·1)
18·3% (14·4-24·0)
34·0% (28·7-41·4)
20·1% (16·0-30·6)
12·5% (10·6-15·2)
21·0% (18·6-27·5)
39·8% (21·8-72·7)
18·6% (14·2-32·8)
30·2% (27·3-36·1)

54·3% (27·0-69·1)
57·9% (47·7-65·5)
57·3% (48·0-65·1)
55·9% (50·3-62·5)
57·5% (41·7-66·4)
50·4% (15·8-71·4)
48·6% (36·8-59·9)
41·8% (35·0-52·5)
45·3% (37·3-50·9)
41·4% (19·4-53·3)
44·9% (34·6-55·0)
43·8% (24·6-58·2)
51·6% (27·0-70·0)
60·7% (53·2-66·9)
29·3% (12·7-42·8)
48·0% (31·5-61·3)
49·2% (39·2-54·4)
46·4% (34·6-54·4)
47·0% (33·5-58·2)
43·4% (33·4-53·2)
41·4% (33·8-48·9)
50·8% (32·1-61·7)
56·7% (45·9-66·2)
61·9% (47·0-69·4)
33·4% (16·5-51·7)
55·1% (29·8-69·6)
57·8% (48·1-64·1)

3·9% (3·4-4·3)

1·5% (0·7-2·2)

3·6% (3·0-4·1)

0·7% (0·5-0·8)

3·0% (2·7-3·4)

1·1% (0·9-1·4)

4·2% (3·9-4·6)

0·7% (0·6-0·9)

1·7% (1·2-1·9)

0·9% (0·6-1·1)

1·2% (0·4-1·7)

0·2% (0·1-0·3)

3·6% (3·1-4·0)

1·6% (1·1-2·2)

3·2% (2·9-3·5)

0·7% (0·6-0·9)

4·1% (3·4-4·6)

1·2% (1·0-1·5)

2·9% (1·4-3·7)

1·1% (0·4-1·5)

4·9% (3·7-6·0)

1·4% (0·9-1·9)

6·9% (3·7-9·0)

1·8% (0·9-2·5)

3·7% (1·9-5·0)

1·3% (0·7-2·0)

4·8% (4·2-5·2)

1·5% (1·1-1·9)

2·5% (1·1-3·7)

0·9% (0·4-1·5)

4·5% (2·9-5·7)

1·3% (0·7-1·7)

5·1% (4·1-5·7)

1·4% (1·0-1·8)

3·6% (2·6-5·6)

1·5% (1·1-1·9)

3·0% (2·2-3·7)

1·5% (1·0-1·9)

2·7% (2·1-3·3)

1·3% (0·9-1·7)

6·3% (5·1-7·6)

1·1% (0·9-1·4)

3·4% (2·1-4·1)

1·5% (1·0-2·0)

5·4% (4·3-6·3)

1·6% (1·1-1·9)

6·6% (5·0-7·4)

1·7% (1·3-2·3)

2·7% (1·3-4·1)

0·8% (0·4-1·4)

4·4% (3·8-5·1)

1·2% (0·7-1·6)

2·9% (2·4-3·2)

1·0% (0·7-1·3)

(Table continues on next page)

2364

www.thelancet.com Vol 399 June 25, 2022

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Valencian Community

13300 (10500-16100)

Sweden

16600 (15100-19000)

Switzerland

13000 (11000-15700)

UK

168000

(167000-171000)

England

143000 (143000-143000)

Northern Ireland

4420 (3770-5790)

Scotland

12500 (11900-14300)

Wales

8800 (8800-8800)

Latin America and Caribbean

2470000 (1870000-3370000)

Andean Latin America

530000 (375000-755000)

Bolivia

135000 (87000-205000)

Ecuador

94200 (66900-134000)

Peru

301000

(217000-420000)

Caribbean

87200 (54600-147000)

Antigua and Barbuda

114 (114-114)

The Bahamas

897 (660-1440)

Barbados

394 (211-635)

Belize

805 (535-1360)

Bermuda

140 (106-206)

Cuba

25100

(13400-52900)

Dominica

105 (55-178)

Dominican Republic

17900 (8510-31900)

Grenada

247 (200-412)

Guyana

2200 (968-4290)

Haiti

22200

(9690-40600)

Jamaica

5400 (2710-9530)

Puerto Rico

5360 (3890-6480)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

271·4 (215·4-329·2)
162·8 (147·6-186·3)
147·7 (125·3-179·1)
250·5 (248·6-254·1)
252·1 (252·1-252·1)
228·4 (194·8-299·0)
227·2 (216·3-258·3)
276·0 (276·0-276·0)
423·2 (320·3-576·3)
833·9 (590·3-1186·7)
1125·0 (723·9-1708·8)
535·3 (380·6-764·5)
885·6 (639·2-1234·9)
184·8 (115·7-312·5)
128·7 (128·7-128·7)
238·0 (175·2-383·2)
132·4 (70·9-213·2)
196·2 (130·5-331·4)
219·1 (165·8-321·7)
220·6 (118·0-465·5)
152·8 (80·2-258·7)
164·7 (78·2-293·3)
239·3 (193·6-399·0)
285·1 (125·6-556·6)
178·7 (78·1-327·3)
192·1 (96·4-339·1)
152·2 (110·5-184·0)

997000 (829000-1220000)
2320000 (1980000-2800000)
1770000 (1490000-2200000)
19400000 (18200000-20600000)
16700000 (15500000-17900000)
474000 (421000-582000)
1430000 (1300000-1580000)
817000 (724000-1010000)
375000000 (334000000-417000000)
50400000 (36500000-60500000)
12600000 (9320000-14500000)
14100000 (10100000-17000000)
23700000 (15900000-30900000)
12100000 (6460000-17300000)
17400 (10100-26000)
116000 (59400-178000)
48400 (35200-64200)
170000 (74200-287000)
10000 (8430-13200)
2080000 (1510000-3000000)
13900 (9080-21100)
3680000 (1530000-5630000)
25100 (11600-38000)
351000 (142000-600000)
3790000 (1120000-6410000)
582000 (296000-894000)
450000 (348000-576000)

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

20·4 (16·9-25·0)
22·7 (19·3-27·4)
20·2 (17·0-25·0)
28·8 (27·0-30·7)
29·4 (27·4-31·6)
24·5 (21·8-30·1)
26·0 (23·6-28·7)
25·6 (22·7-31·6)
64·1 (57·2-71·3)
79·3 (57·4-95·1)
104·9 (77·6-121·0)
80·2 (57·2-96·7)
69·8 (46·8-90·8)
25·7 (13·7-36·7)
19·7 (11·4-29·4)
30·8 (15·8-47·1)
16·3 (11·8-21·6)
41·5 (18·1-70·0)
15·6 (13·2-20·6)
18·3 (13·3-26·4)
20·2 (13·2-30·7)
33·8 (14·1-51·7)
24·3 (11·3-36·8)
45·6 (18·5-77·9)
30·5 (9·0-51·7)
20·7 (10·5-31·8)
12·8 (9·9-16·4)

20·0% (16·6-24·5)
22·4% (19·2-27·0)
19·7% (16·7-24·4)
27·7% (26·1-29·5)
28·3% (26·4-30·4)
23·6% (21·0-28·5)
25·0% (22·8-27·5)
24·7% (22·0-30·1)
57·4% (51·7-63·1)
69·0% (52·9-83·1)
85·8% (69·1-91·0)
70·2% (53·5-83·8)
62·3% (44·5-80·9)
25·0% (13·5-35·2)
16·9% (9·1-26·3)
29·5% (15·0-44·8)
15·4% (11·1-20·5)
38·6% (17·6-62·5)
12·1% (10·2-16·3)
17·9% (13·2-25·4)
18·1% (11·6-28·6)
33·3% (14·0-50·6)
23·0% (10·4-35·2)
42·7% (18·0-69·9)
29·6% (9·0-49·0)
20·6% (10·5-31·6)
12·6% (9·8-16·1)

54·8% (44·2-65·0)
52·2% (42·7-60·6)
56·7% (45·4-66·7)
54·2% (51·0-57·5)
53·5% (49·9-57·2)
66·8% (54·0-74·2)
54·1% (48·8-59·5)
61·4% (49·6-68·8)
10·8% (9·7-12·1)
6·6% (5·4-9·0)
4·3% (3·7-5·7)
3·8% (3·1-5·2)
9·6% (7·2-14·0)
17·4% (11·3-30·2)
25·1% (15·7-40·7)
21·3% (12·7-38·1)
52·5% (38·5-69·6)
20·1% (10·5-40·4)
58·0% (43·4-67·9)
47·9% (32·1-63·5)
44·4% (27·8-63·9)
12·4% (7·2-26·5)
25·9% (15·5-50·6)
12·2% (6·3-26·3)
0·8% (0·4-2·2)
17·1% (10·2-30·7)
42·5% (32·5-53·9)

4·3% (3·5-5·2)

1·4% (1·0-1·8)

2·6% (2·1-3·0)

0·7% (0·6-0·9)

2·1% (1·6-2·4)

0·8% (0·6-1·0)

3·1% (2·9-3·3)

0·9% (0·8-0·9)

3·1% (2·9-3·3)

0·9% (0·8-0·9)

3·1% (2·5-3·5)

1·0% (0·7-1·4)

2·9% (2·6-3·1)

0·9% (0·8-1·1)

4·6% (3·7-5·1)

1·1% (0·9-1·2)

0·9% (0·8-1·1)

0·7% (0·5-0·9)

0·9% (0·7-1·3)

1·1% (0·7-1·7)

0·7% (0·5-1·1)

1·1% (0·7-1·8)

0·8% (0·7-1·2)

0·7% (0·5-1·1)

1·0% (0·9-1·4)

1·3% (0·9-2·0)

1·1% (0·8-1·8)

0·8% (0·5-1·4)

1·1% (0·9-1·5)

0·7% (0·4-1·2)

1·3% (1·0-1·8)

0·9% (0·5-1·6)

1·7% (1·3-2·4)

1·1% (0·7-1·6)

0·8% (0·6-1·2)

0·6% (0·3-1·3)

2·7% (1·9-3·8)

1·4% (1·0-2·1)

2·2% (1·6-2·9)

1·2% (0·6-2·1)

1·1% (0·8-1·6)

0·9% (0·5-1·5)

0·8% (0·6-1·3)

0·5% (0·3-1·1)

1·3% (1·0-1·8)

1·1% (0·6-2·3)

0·9% (0·6-1·4)

0·7% (0·4-1·6)

0·6% (0·4-1·2)

0·8% (0·3-2·3)

1·4% (1·1-1·9)

1·0% (0·5-1·9)

2·2% (1·7-2·8)

1·2% (0·8-1·7)

(Table continues on next page)

www.thelancet.com Vol 399 June 25, 2022

2365

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Saint Kitts and Nevis

44 (28-68)

Saint Lucia

417 (266-711)

Saint Vincent and the Grenadines

195 (95-344)

Suriname

2230 (1190-4700)

Trinidad and Tobago

3030 (1850-5440)

Virgin Islands

459 (248-861)

Central Latin America

1120000 (794000-1560000)

Colombia

156000 (128000-209000)

Costa Rica

7210 (7210-7210)

El Salvador

22600 (15500-32100)

Guatemala

43900 (27400-64600)

Honduras

47500 (30900-76500)

Mexico

678000 (480000-951000)

Aguascalientes

5880 (4280-8080)

Baja California

19200 (13100-26900)

Baja California Sur

3340 (3000-4560)

Campeche

4240 (3210-6010)

Chiapas

19600 (13300-27500)

Chihuahua

21200 (14600-29000)

Coahuila

17700 (12300-24800)

Colima

2500 (2460-2800)

Durango

7120 (4770-9750)

Guanajuato

27300 (19300-38600)

Guerrero

13600 (9510-18900)

Hidalgo

13800 (9910-19500)

Jalisco

29400 (22900-41300)

México

124000 (87400-176000)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

73·8 (46·9-113·4)
238·9 (152·3-407·1)
172·0 (83·9-303·8)
387·4 (206·4-815·3)
218·6 (133·6-392·4)
441·6 (238·2-827·9)
446·5 (317·5-625·5)
327·3 (267·4-438·0)
153·0 (152·8-152·8)
361·7 (248·3-512·7)
246·9 (154·3-363·6)
483·8 (314·5-779·1)
542·6 (383·9-761·5)
424·5 (309·1-583·3)
496·7 (338·4-696·6)
406·3 (364·9-554·2)
456·1 (345·7-646·6)
334·0 (225·7-468·1)
601·2 (413·9-820·8)
565·5 (392·1-792·6)
333·1 (328·5-374·2)
396·9 (265·9-544·0)
442·9 (312·8-627·0)
366·2 (256·6-510·9)
456·7 (327·6-643·2)
359·5 (280·3-505·2)
717·5 (504·4-1017·3)

7120 (4610-11700)
46100 (24500-75200)
20400 (11400-31900)
321000 (159000-491000)
362000 (167000-595000)
26800 (14200-44800)
164000000 (143000000-185000000)
23200000 (17900000-28600000)
2260000 (1430000-3130000)
2340000 (1510000-3270000)
12500000 (8460000-17100000)
9360000 (7040000-11500000)
92200000 (84200000-101000000)
760000 (380000-1050000)
3540000 (2530000-4240000)
670000 (430000-931000)
578000 (398000-848000)
2300000 (1320000-3550000)
1530000 (560000-2860000)
2880000 (2040000-3470000)
390000 (224000-590000)
1510000 (889000-2010000)
5510000 (3820000-6920000)
2000000 (1600000-2340000)
2630000 (1840000-3340000)
4980000 (3670000-6590000)
13300000 (10300000-16500000)

12·0 (7·8-19·6)
26·4 (14·0-43·0)
18·1 (10·1-28·2)
55·8 (27·6-85·2)
26·1 (12·1-42·9)
25·7 (13·7-43·1)
65·6 (57·2-74·0)
48·5 (37·4-59·8)
48·0 (30·4-66·4)
37·4 (24·1-52·3)
70·4 (47·6-95·9)
95·3 (71·7-117·4)
73·8 (67·4-80·9)
54·9 (27·4-76·0)
91·6 (65·5-110·0)
81·4 (52·3-113·1)
62·2 (42·8-91·2)
39·0 (22·4-60·3)
43·4 (15·9-81·1)
91·9 (65·3-110·8)
52·0 (29·9-78·7)
84·1 (49·6-112·3)
89·3 (62·0-112·3)
54·0 (43·3-63·1)
87·0 (60·8-110·6)
61·0 (44·9-80·7)
76·9 (59·2-95·3)

8·8% (4·4-17·7)
24·3% (12·9-39·2)
16·5% (9·0-26·6)
52·1% (26·5-78·4)
25·1% (11·9-40·0)
23·4% (12·0-39·1)
59·1% (52·2-65·9)
45·2% (35·3-54·1)
44·6% (28·9-60·9)
36·0% (23·6-49·4)
62·8% (44·8-81·9)
81·4% (66·4-91·7)
65·7% (61·1-70·8)
51·2% (26·7-70·0)
79·2% (59·4-89·4)
70·5% (48·6-88·6)
56·2% (40·1-78·6)
37·1% (21·9-55·6)
41·5% (15·7-76·0)
80·4% (60·4-92·1)
47·8% (28·8-69·7)
73·2% (46·6-90·6)
78·2% (57·9-92·1)
50·6% (41·9-59·0)
75·4% (55·7-89·4)
56·0% (42·5-71·6)
69·9% (55·0-82·7)

41·6% (23·9-60·3)
30·0% (17·0-52·1)
34·2% (20·5-57·0)
17·4% (10·3-31·8)
20·9% (11·6-40·5)
30·0% (16·7-52·4)
7·7% (6·7-8·7)
22·2% (17·7-28·3)
26·2% (18·1-39·6)
5·4% (3·7-7·9)
5·1% (3·6-7·3)
4·1% (3·3-5·4)
4·2% (3·9-4·6)
5·4% (3·5-9·8)
2·4% (1·9-3·2)
8·9% (6·1-13·3)
4·3% (2·9-6·1)
1·1% (0·7-1·8)
6·2% (2·6-13·4)
3·5% (2·8-4·8)
9·2% (5·6-14·8)
3·6% (2·5-5·6)
3·7% (2·8-5·2)
3·9% (3·3-4·8)
2·5% (1·9-3·4)
3·4% (2·5-4·5)
3·0% (2·3-3·8)

1·4% (1·0-1·9)

0·7% (0·4-1·2)

1·5% (1·1-2·0)

1·0% (0·6-1·9)

1·3% (1·0-1·9)

1·0% (0·5-2·2)

1·1% (0·9-1·8)

0·8% (0·4-1·8)

1·5% (1·2-2·1)

1·2% (0·7-2·2)

0·8% (0·5-1·4)

1·9% (1·0-3·6)

0·7% (0·6-0·8)

0·7% (0·5-1·0)

0·9% (0·7-1·0)

0·7% (0·5-1·0)

1·4% (1·0-2·2)

0·3% (0·2-0·5)

0·7% (0·6-0·9)

1·0% (0·6-1·8)

0·4% (0·3-0·6)

0·4% (0·2-0·6)

0·5% (0·4-0·7)

0·5% (0·3-0·8)

0·7% (0·6-0·7)

0·7% (0·5-1·1)

1·0% (0·6-1·8)

0·9% (0·5-1·7)

0·6% (0·5-0·8)

0·6% (0·4-1·0)

0·7% (0·5-1·1)

0·5% (0·3-0·8)

0·7% (0·5-1·0)

0·8% (0·5-1·3)

0·2% (0·1-0·4)

0·9% (0·5-1·5)

1·3% (0·6-2·9)

1·9% (0·7-4·0)

0·5% (0·4-0·7)

0·7% (0·4-1·0)

1·2% (0·7-1·9)

0·7% (0·4-1·1)

0·4% (0·3-0·7)

0·5% (0·3-1·0)

0·5% (0·4-0·7)

0·5% (0·3-0·9)

0·6% (0·5-0·8)

0·7% (0·5-1·0)

0·7% (0·5-0·9)

0·5% (0·3-0·9)

0·7% (0·5-1·0)

0·6% (0·4-0·9)

0·7% (0·6-0·9)

1·0% (0·6-1·4)

(Table continues on next page)

2366

www.thelancet.com Vol 399 June 25, 2022

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Mexico City

90700 (64900-127000)

Michoacán de Ocampo

17200 (11800-24600)

Morelos

9600 (7010-13700)

Nayarit

3640 (3120-4950)

Nuevo León

27900 (19700-39500)

Oaxaca

15000 (10100-21200)

Puebla

43600 (30600-63100)

Querétaro

8970 (6900-12300)

Quintana Roo

7570 (5200-10700)

San Luis Potosí

14200 (10000-20000)

Sinaloa

15200 (10300-21700)

Sonora

15700 (10700-21900)

Tabasco

13700 (9290-19400)

Tamaulipas

18500 (12600-26500)

Tlaxcala

11500 (7940-16400)

Veracruz de Ignacio de la Llave

37900 (26300-54200)

Yucatán

9640 (6480-14000)

Zacatecas

8240 (5780-11500)

Nicaragua

17600 (11400-25400)

Panama

8940 (7330-12900)

Venezuela

134000 (86800-193000)

Tropical Latin America

739000 (651000-933000)

Brazil

720000 (634000-907000)

Acre

2200

(1840-2750)

Alagoas

6660 (6320-8280)

Amapá

2890 (1990-3820)

Amazonas

17900 (13800-24000)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

1029·0 (735·8-1436·0)
368·5 (253·4-526·1)
487·3 (356·0-698·2)
296·5 (253·7-403·0)
530·1 (373·7-748·9)
361·8 (244·9-510·4)
672·6 (471·4-973·8)
410·4 (315·9-564·0)
444·0 (304·6-625·0)
505·6 (355·1-709·6)
516·3 (348·2-736·2)
526·9 (358·6-736·7)
551·5 (373·8-780·4)
527·8 (359·0-757·7)
860·8 (594·6-1230·1)
464·7 (323·1-665·0)
441·3 (296·6-639·3)
514·1 (360·6-714·4)
270·2 (175·4-390·1)
214·9 (176·2-309·6)
478·1 (309·1-687·4)
330·5 (290·9-417·2)
332·1 (292·7-418·5)
237·4 (198·2-297·0)
181·9 (172·6-226·3)
342·5 (235·2-452·4)
424·0 (325·9-568·4)

8450000 (7030000-9510000)
2300000 (1740000-2970000)
1500000 (1010000-2170000)
726000 (496000-1040000)
4660000 (3620000-5310000)
2090000 (1490000-2700000)
5820000 (4420000-6880000)
1130000 (394000-2040000)
1710000 (1300000-2050000)
1690000 (1220000-2160000)
2470000 (1740000-3190000)
2530000 (1990000-3110000)
2330000 (1710000-2820000)
2500000 (1730000-3310000)
1100000 (810000-1420000)
5540000 (3820000-7410000)
2190000 (1390000-2630000)
915000 (574000-1300000)
3860000 (3120000-4500000)
1740000 (1330000-2230000)
16600000 (13500000-19400000)
148000000 (122000000-174000000)
143000000 (118000000-169000000)
501000 (307000-735000)
2130000 (1080000-3320000)
653000 (470000-821000)
3260000 (2180000-4370000)

95·9 (79·7-107·9)
49·3 (37·3-63·7)
76·4 (51·4-110·2)
59·1 (40·4-84·3)
88·3 (68·7-100·7)
50·5 (35·9-65·2)
89·7 (68·2-106·1)
51·9 (18·0-93·2)
100·0 (76·2-119·9)
60·0 (43·4-76·8)
83·7 (58·9-108·1)
84·9 (66·9-104·6)
93·9 (68·9-113·7)
71·4 (49·3-94·4)
82·4 (60·6-106·3)
67·9 (46·8-90·9)
100·2 (63·4-120·2)
57·1 (35·8-80·8)
59·3 (48·0-69·1)
41·8 (32·0-53·5)
59·3 (48·0-69·1)
66·1 (54·6-78·0)
66·0 (54·4-78·0)
54·1 (33·1-79·4)
58·1 (29·4-90·8)
77·3 (55·6-97·2)
77·3 (51·8-103·4)

83·5% (71·3-89·1)
46·5% (36·0-59·4)
69·0% (48·9-90·8)
54·0% (38·1-75·3)
76·0% (62·3-84·9)
47·2% (34·2-58·7)
78·0% (62·4-88·2)
48·0% (17·8-80·8)
82·6% (66·5-91·0)
55·6% (41·8-69·4)
72·8% (54·5-86·4)
74·4% (60·8-85·3)
79·3% (61·5-88·9)
63·6% (46·6-80·7)
73·8% (57·7-89·9)
60·8% (43·8-76·6)
82·2% (57·4-91·7)
53·6% (34·7-73·0)
55·4% (46·1-63·5)
40·5% (31·4-51·1)
54·3% (45·1-62·7)
59·2% (50·1-68·1)
59·0% (50·0-68·1)
49·8% (31·9-69·2)
52·8% (28·1-77·5)
68·1% (51·3-82·2)
67·7% (48·7-86·2)

11·8% (10·4-14·1)
3·3% (2·5-4·2)
3·5% (2·3-4·9)
4·9% (3·3-6·9)
4·5% (3·9-5·7)
4·1% (3·1-5·6)
2·2% (1·8-2·8)
11·2% (4·9-25·2)
3·6% (2·9-4·6)
6·4% (4·9-8·6)
3·1% (2·3-4·3)
4·7% (3·8-6·0)
6·3% (5·1-8·4)
4·3% (3·1-6·0)
2·7% (2·1-3·6)
2·3% (1·7-3·3)
3·6% (2·8-5·4)
4·8% (3·2-7·3)
3·9% (2·7-4·9)
28·0% (21·4-35·8)
7·6% (6·2-9·8)
15·4% (12·9-18·4)
15·5% (13·0-18·7)
18·4% (12·0-28·7)
12·3% (7·3-22·4)
19·4% (15·1-26·3)
13·6% (9·8-19·7)

1·0% (0·9-1·2)

1·1% (0·7-1·6)

0·7% (0·5-0·9)

0·8% (0·5-1·2)

0·7% (0·5-1·0)

0·7% (0·4-1·1)

0·9% (0·6-1·3)

0·5% (0·3-0·8)

0·7% (0·6-0·9)

0·6% (0·4-0·9)

0·6% (0·4-0·8)

0·7% (0·5-1·3)

0·5% (0·5-0·7)

0·8% (0·5-1·4)

1·3% (0·6-3·0)

1·0% (0·4-2·3)

0·5% (0·4-0·7)

0·5% (0·3-0·7)

0·7% (0·5-0·9)

0·9% (0·6-1·4)

0·8% (0·6-1·0)

0·6% (0·4-1·0)

0·7% (0·6-0·9)

0·6% (0·4-1·0)

0·5% (0·4-0·7)

0·6% (0·4-1·0)

0·5% (0·4-0·7)

0·8% (0·4-1·2)

0·6% (0·4-0·8)

1·1% (0·7-1·7)

0·6% (0·4-0·8)

0·7% (0·4-1·1)

0·6% (0·4-0·8)

0·5% (0·3-0·8)

0·8% (0·5-1·1)

0·9% (0·6-1·5)

0·6% (0·5-0·8)

0·5% (0·3-0·7)

0·7% (0·6-0·9)

0·5% (0·3-0·8)

0·9% (0·7-1·1)

0·8% (0·5-1·2)

1·2% (1·0-1·5)

0·5% (0·4-0·6)

1·2% (1·0-1·5)

0·5% (0·4-0·6)

0·9% (0·6-1·4)

0·5% (0·3-0·7)

1·0% (0·6-1·9)

0·3% (0·2-0·6)

0·9% (0·7-1·2)

0·5% (0·3-0·6)

1·1% (0·8-1·6)

0·6% (0·4-0·8)

(Table continues on next page)

www.thelancet.com Vol 399 June 25, 2022

2367

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Bahia

39800 (29800-52600)

Ceará

45400 (34800-59100)

Distrito Federal

11000 (10900-11500)

Espírito Santo

15200 (13000-19800)

Goiás

26900 (24300-33800)

Maranhão

28400 (19600-44100)

Mato Grosso

14700 (13700-18800)

Mato Grosso do Sul

9690 (9650-10400)

Minas Gerais

65600 (55800-85800)

Pará

21700

(16700-29600)

Paraíba

9470 (9460-9690)

Paraná

41600 (40500-49000)

Pernambuco

28100 (21100-36400)

Piauí

8940

(7130-11000)

Rio de Janeiro

73400 (68600-92400)

Rio Grande do Norte

8080

(7400-9770)

Rio Grande do Sul

35900 (35800-37700)

Rondônia

8380 (6600-10200)

Roraima

2040 (2020-2210)

Santa Catarina

19900 (19800-21000)

São Paulo

165000 (153000-212000)

Sergipe

6050 (6030-6360)

Tocantins

4900 (3890-6010)

Paraguay

19600 (16400-26700)

North Africa and Middle East

1430000 (986000-2160000)

Afghanistan

164000 (92400-274000)

Algeria

44300 (31900-62000)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

249·5 (186·8-330·0)
452·2 (346·6-588·6)
362·7 (361·5-381·3)
382·7 (327·9-497·3)
391·4 (353·5-491·3)
339·2 (234·3-527·7)
408·7 (380·8-523·0)
341·1 (339·5-367·1)
302·6 (257·4-395·5)
234·7 (181·1-320·3)
216·2 (215·8-221·1)
365·4 (355·7-430·5)
277·1 (208·8-359·2)
242·1 (192·9-297·6)
415·5 (388·0-522·6)
216·0 (198·0-261·3)
317·8 (316·5-333·8)
471·6 (371·5-572·4)
340·8 (337·4-369·5)
277·8 (276·8-293·2)
361·9 (335·7-465·0)
251·2 (250·4-264·2)
298·5 (237·0-365·9)
282·3 (236·9-384·6)
235·6 (162·0-354·6)
429·1 (241·3-715·9)
105·7 (76·2-148·1)

10600000 (6230000-14400000)
7860000 (5700000-10300000)
1750000 (805000-3600000)
2890000 (1980000-4050000)
6190000 (4990000-7130000)
6460000 (2250000-9300000)
2900000 (2190000-3590000)
1920000 (1110000-2840000)
18900000 (12600000-24800000)
5950000 (3370000-8410000)
3220000 (1980000-4460000)
7290000 (5560000-9120000)
4960000 (3240000-6380000)
2610000 (1490000-3580000)
8760000 (6300000-11800000)
1930000 (1450000-2490000)
4010000 (2930000-7750000)
1320000 (1020000-1690000)
489000 (373000-635000)
5470000 (4180000-7460000)
28800000 (22200000-35600000)
852000 (666000-1690000)
1400000 (896000-1810000)
4830000 (3370000-6210000)
382000000 (281000000-481000000)
39600000 (19600000-47100000)
7800000 (4760000-13100000)

66·5 (39·0-90·1)
78·4 (56·8-102·7)
57·9 (26·6-118·7)
72·7 (49·8-101·9)
90·1 (72·5-103·7)
77·3 (26·9-111·2)
80·4 (61·0-99·7)
67·7 (38·9-100·1)
87·1 (58·3-114·5)
64·4 (36·5-90·9)
73·5 (45·1-101·8)
64·0 (48·8-80·0)
48·9 (32·0-63·0)
70·6 (40·3-97·0)
49·6 (35·6-66·8)
51·6 (38·8-66·6)
35·5 (25·9-68·6)
74·6 (57·7-95·1)
81·7 (62·3-106·0)
76·4 (58·4-104·3)
63·2 (48·9-78·1)
35·4 (27·7-70·0)
85·2 (54·6-110·3)
69·7 (48·6-89·7)
62·7 (46·2-79·0)
103·4 (51·2-123·1)
18·6 (11·4-31·3)

59·7% (37·4-77·1)
68·5% (52·4-85·7)
51·5% (25·8-91·3)
64·2% (45·8-81·8)
78·0% (63·4-86·1)
67·1% (26·1-90·6)
70·2% (55·5-84·7)
60·5% (37·0-80·8)
75·4% (53·8-93·2)
57·9% (34·7-76·4)
65·0% (42·2-85·7)
57·9% (45·5-70·2)
45·6% (30·6-57·8)
62·6% (38·1-80·4)
46·0% (34·3-58·8)
47·8% (37·1-59·1)
33·6% (25·1-62·1)
66·0% (52·1-80·2)
71·1% (55·3-89·8)
67·5% (52·8-88·1)
57·4% (45·2-70·2)
33·5% (26·9-63·3)
73·5% (50·0-90·0)
62·8% (45·5-76·7)
55·3% (40·8-67·1)
84·8% (47·4-93·4)
18·4% (11·3-30·5)

12·4% (8·7-20·2)
12·4% (9·2-16·6)
35·5% (14·4-64·2)
22·2% (15·2-31·2)
15·2% (13·0-18·6)
6·5% (3·9-16·2)
19·3% (15·3-25·0)
20·7% (13·3-34·2)
12·1% (8·9-17·4)
10·8% (7·2-18·0)
14·8% (10·3-23·3)
22·0% (17·3-28·3)
13·4% (10·0-19·7)
13·0% (9·0-21·6)
15·7% (11·3-21·2)
20·0% (15·2-26·1)
39·5% (19·2-50·8)
21·2% (16·3-26·9)
26·8% (20·1-34·3)
23·0% (16·5-29·4)
15·6% (12·4-19·9)
34·1% (16·5-41·7)
17·1% (12·8-25·9)
9·8% (7·4-13·7)
6·8% (5·2-8·9)
0·4% (0·3-0·8)
2·9% (1·6-4·4)

0·7% (0·5-1·1)

0·4% (0·3-0·7)

0·8% (0·6-1·1)

0·6% (0·4-0·8)

3·0% (1·2-5·4)

0·8% (0·3-1·4)

0·5% (0·3-0·7)

0·6% (0·4-0·9)

1·1% (1·0-1·4)

0·4% (0·4-0·6)

0·3% (0·2-0·8)

0·5% (0·3-1·2)

1·0% (0·8-1·3)

0·5% (0·4-0·7)

1·7% (1·1-2·8)

0·5% (0·3-0·9)

1·0% (0·7-1·4)

0·4% (0·2-0·6)

0·8% (0·5-1·3)

0·4% (0·3-0·6)

0·9% (0·6-1·4)

0·3% (0·2-0·5)

1·7% (1·4-2·2)

0·6% (0·5-0·8)

0·8% (0·6-1·2)

0·6% (0·4-0·9)

0·9% (0·6-1·5)

0·4% (0·2-0·6)

2·0% (1·4-2·7)

0·9% (0·6-1·2)

1·0% (0·7-1·3)

0·4% (0·3-0·6)

3·0% (1·4-3·8)

1·0% (0·5-1·2)

1·1% (0·8-1·4)

0·6% (0·5-0·9)

0·9% (0·7-1·2)

0·4% (0·3-0·6)

1·4% (1·0-1·7)

0·4% (0·3-0·5)

1·8% (1·5-2·3)

0·6% (0·5-0·9)

1·9% (0·9-2·4)

0·7% (0·4-0·9)

0·7% (0·5-1·0)

0·4% (0·3-0·5)

1·1% (0·9-1·4)

0·4% (0·3-0·6)

1·0% (0·8-1·5)

0·4% (0·2-0·7)

0·5% (0·3-0·9)

0·5% (0·2-1·1)

1·2% (0·9-1·7)

0·6% (0·3-1·1)

(Table continues on next page)

2368

www.thelancet.com Vol 399 June 25, 2022

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Bahrain

3570 (2510-5160)

Egypt

204000 (143000-292000)

Iran

234000

(154000-389000)

Iraq

156000

(97500-265000)

Jordan

21100 (13200-34300)

Kuwait

3140 (2460-4460)

Lebanon

30300 (20800-50400)

Libya

29600 (18800-47400)

Morocco

136000 (86600-233000)

Oman

10800 (7990-14200)

Palestine

10600 (7010-16000)

Qatar

1340 (898-1890)

Saudi Arabia

27900 (19600-38200)

Sudan

66200 (42900-101000)

Syria

21200

(14000-30300)

Tunisia

62400 (43900-102000)

Turkey

145000 (104000-217000)

United Arab Emirates

8600 (5540-12800)

Yemen

53900 (28800-91300)

South Asia

4500000 (3190000-6340000)

Bangladesh

353000 (236000-508000)

Bhutan

108 (55-158)

India

3480000

(2520000-4910000)

Andhra Pradesh

166000 (119000-252000)

Arunachal Pradesh

1520 (767-2310)

Assam

101000 (66000-145000)

Bihar

276000 (175000-396000)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

247·4 (174·1-357·7)
206·2 (144·7-294·9)
277·5 (183·1-461·9)
370·8 (231·5-628·3)
181·3 (113·5-295·0)
70·8 (55·5-100·8)
585·2 (401·6-974·0)
439·8 (279·7-703·3)
377·6 (240·7-649·2)
234·9 (174·2-310·2)
214·8 (141·5-322·4)
46·9 (31·4-66·1)
78·1 (55·0-106·9)
162·2 (105·1-248·1)
146·4 (96·6-209·4)
539·5 (379·2-880·4)
178·2 (127·7-267·3)
93·0 (59·9-138·0)
171·2 (91·5-289·8)
249·1 (176·8-351·0)
221·7 (148·4-319·2)
14·3 (7·3-20·9)
250·1 (181·6-353·4)
307·2 (219·0-465·6)
88·5 (44·6-133·9)
279·7 (183·1-403·5)
226·3 (143·1-324·1)

875000 (552000-1180000)
75300000 (15200000-114000000)
56900000 (40500000-86000000)
41900000 (26200000-50200000)
8330000 (5440000-10300000)
1970000 (1110000-3320000)
3750000 (2430000-4880000)
6880000 (4660000-8110000)
27800000 (13600000-39100000)
2060000 (1340000-2980000)
4730000 (3000000-5830000)
1950000 (1230000-2380000)
8150000 (4870000-13900000)
21100000 (7720000-34900000)
3010000 (1350000-5160000)
10600000 (6280000-13600000)
44100000 (26200000-70200000)
2460000 (1350000-3690000)
12500000 (4210000-26200000)
1340000000 (1200000000-1490000000)
137000000 (98900000-185000000)
20200 (14200-27500)
1000000000 (881000000-1120000000)
43600000 (28400000-61000000)
675000 (434000-1230000)
28700000 (18400000-39700000)
94900000 (39700000-117000000)

60·6 (38·3-82·1)
76·0 (15·3-114·9)
67·5 (48·0-102·0)
99·4 (62·1-119·2)
71·6 (46·8-88·1)
44·4 (25·1-75·1)
72·5 (46·9-94·3)
102·1 (69·1-120·5)
77·3 (37·8-108·9)
44·9 (29·3-64·9)
95·4 (60·6-117·7)
68·0 (43·0-83·2)
22·8 (13·6-38·9)
51·7 (18·9-85·6)
20·7 (9·3-35·6)
91·6 (54·3-117·8)
54·2 (32·2-86·3)
26·6 (14·6-40·0)
39·6 (13·4-83·2)
74·3 (66·5-82·6)
86·0 (62·1-116·0)
2·7 (1·9-3·6)
72·1 (63·4-80·3)
80·5 (52·4-112·5)
39·2 (25·2-71·4)
79·6 (50·9-110·1)
77·7 (32·5-95·8)

55·2% (36·0-71·7)
65·4% (15·1-89·4)
60·5% (45·1-85·3)
82·4% (57·1-91·7)
64·9% (44·9-77·4)
41·9% (24·6-66·3)
67·3% (45·6-83·7)
83·8% (63·8-91·7)
67·2% (36·0-86·3)
42·0% (28·1-61·0)
79·9% (56·3-90·5)
61·0% (41·4-72·8)
22·4% (13·6-37·3)
49·7% (18·8-77·6)
20·2% (9·2-33·9)
77·9% (51·1-91·2)
49·6% (31·1-76·6)
26·0% (14·5-38·4)
37·5% (13·1-71·1)
65·8% (59·5-71·5)
74·3% (57·2-92·4)
2·2% (1·3-3·3)
64·3% (57·7-70·4)
70·2% (48·4-93·4)
37·1% (24·3-64·9)
71·7% (47·2-95·8)
69·1% (31·2-83·3)

32·9% (23·4-50·2)
0·7% (0·3-2·3)
11·1% (7·1-15·1)
5·1% (4·1-8·0)
11·5% (9·1-17·1)
23·0% (12·4-37·2)
18·3% (13·6-27·4)
5·5% (4·6-8·0)
3·7% (2·4-7·0)
15·4% (10·3-22·7)
9·4% (7·3-14·3)
12·9% (10·2-19·7)
7·2% (4·0-11·3)
0·2% (0·1-0·5)
1·8% (0·9-3·5)
7·0% (5·3-11·5)
23·0% (13·6-36·4)
32·4% (20·1-54·9)
0·1% (0·0-0·2)
2·8% (2·5-3·2)
1·2% (0·9-1·6)
13·4% (9·5-18·4)
3·4% (3·1-3·9)
5·0% (3·4-7·3)
8·8% (4·6-12·7)
2·3% (1·6-3·4)
0·8% (0·6-1·8)

1·3% (1·0-1·6)

0·4% (0·2-0·7)

1·0% (0·8-1·4)

0·4% (0·2-1·8)

1·3% (1·0-1·8)

0·4% (0·2-0·8)

0·9% (0·7-1·3)

0·4% (0·2-0·8)

0·8% (0·6-1·3)

0·3% (0·2-0·5)

1·2% (1·0-1·5)

0·2% (0·1-0·3)

1·8% (1·4-2·2)

0·9% (0·5-1·5)

1·3% (1·0-1·8)

0·5% (0·3-0·8)

0·9% (0·7-1·4)

0·5% (0·3-1·1)

1·1% (0·7-1·6)

0·5% (0·3-0·9)

0·8% (0·6-1·2)

0·2% (0·1-0·4)

1·8% (1·4-2·8)

0·1% (0·0-0·1)

1·1% (0·8-1·4)

0·4% (0·2-0·6)

0·7% (0·5-1·0)

0·4% (0·2-1·0)

1·3% (1·0-1·8)

0·8% (0·4-1·5)

1·8% (1·3-2·3)

0·6% (0·4-1·2)

1·4% (1·1-1·8)

0·4% (0·2-0·7)

1·3% (1·0-1·8)

0·4% (0·2-0·7)

0·6% (0·4-1·0)

0·6% (0·2-1·6)

1·2% (0·9-1·8)

0·3% (0·2-0·5)

1·3% (1·0-2·0)

0·3% (0·2-0·4)

1·1% (0·8-1·5)

0·5% (0·3-0·8)

1·2% (0·9-1·9)

0·3% (0·3-0·5)

1·5% (1·1-2·1)

0·4% (0·2-0·8)

1·0% (0·7-1·5)

0·2% (0·1-0·4)

1·1% (0·8-1·8)

0·4% (0·2-0·7)

0·9% (0·7-1·5)

0·3% (0·2-0·7)

(Table continues on next page)

www.thelancet.com Vol 399 June 25, 2022

2369

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Chhattisgarh

130000 (88700-188000)

Delhi

53000

(33500-81300)

Goa

3670

(3490-5210)

Gujarat

111000 (78500-147000)

Haryana

113000 (78900-164000)

Himachal Pradesh

28400 (17900-41600)

Jammu and Kashmir

35100

(23100-49100)

Jharkhand

70500 (48500-93800)

Karnataka

244000 (173000-363000)

Kerala

96300 (68000-141000)

Madhya Pradesh

191000 (136000-262000)

Maharashtra

530000 (372000-775000)

Manipur

14900 (9280-22700)

Meghalaya

7530 (4600-10800)

Mizoram

2170 (1340-3280)

Nagaland

4490 (2600-7110)

Odisha

110000 (78600-152000)

Punjab

115000 (76100-175000)

Rajasthan

115000 (78300-160000)

Sikkim

831 (489-1240)

Tamil Nadu

220000 (142000-312000)

Telangana

46600 (32900-63300)

Tripura

7820 (4980-11500)

Uttar Pradesh

443000 (297000-628000)

Uttarakhand

55900 (35900-82500)

West Bengal

184000 (119000-271000)

Nepal

105000 (71800-153000)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

409·0 (279·8-593·9)
272·4 (172·0-417·9)
239·7 (228·4-341·0)
160·4 (113·3-212·0)
389·4 (270·8-562·3)
373·1 (235·4-545·9)
250·7 (165·1-350·4)
186·1 (127·9-247·6)
358·3 (254·1-533·6)
275·5 (194·5-402·6)
215·1 (153·1-295·8)
425·0 (298·2-621·4)
424·9 (264·4-647·7)
220·5 (134·7-314·9)
170·4 (105·2-257·2)
229·5 (133·1-363·5)
235·6 (168·5-325·9)
371·5 (244·9-563·8)
143·1 (97·4-199·1)
125·7 (74·1-187·3)
276·0 (178·5-391·4)
119·8 (84·6-162·5)
194·3 (123·6-284·7)
182·3 (122·3-258·6)
472·7 (303·6-697·8)
184·5 (119·3-272·0)
344·4 (236·0-501·6)

23100000 (17300000-34000000)
19400000 (13700000-23200000)
917000 (614000-1300000)
53600000 (29000000-74000000)
21900000 (15500000-28800000)
4030000 (2950000-5740000)
7230000 (3960000-9500000)
24500000 (8010000-40700000)
47200000 (26400000-60100000)
16100000 (9300000-31600000)
61600000 (27800000-85800000)
73200000 (52700000-116000000)
2950000 (1860000-3660000)
2440000 (1650000-3370000)
810000 (628000-906000)
1300000 (823000-2000000)
44900000 (29700000-50900000)
19000000 (10200000-23700000)
51900000 (30600000-66900000)
330000 (229000-486000)
59700000 (50700000-69800000)
28300000 (13600000-39900000)
2170000 (1590000-3200000)
200000000 (119000000-267000000)
7960000 (4880000-11300000)
61400000 (16300000-89000000)
25400000 (21600000-36400000)

73·0 (54·5-107·1)
99·9 (70·6-119·3)
60·0 (40·2-85·3)
77·4 (41·8-106·9)
75·3 (53·1-98·7)
52·9 (38·7-75·5)
51·6 (28·2-67·8)
64·6 (21·2-107·4)
69·4 (38·8-88·4)
46·0 (26·6-90·3)
69·4 (31·3-96·7)
58·7 (42·3-92·8)
84·1 (52·9-104·4)
71·5 (48·4-98·7)
63·5 (49·3-71·0)
66·3 (42·1-102·4)
96·3 (63·6-109·1)
61·0 (32·8-76·3)
64·5 (38·1-83·3)
49·9 (34·6-73·6)
74·8 (63·5-87·4)
72·7 (35·0-102·6)
54·0 (39·4-79·6)
82·2 (49·1-110·0)
67·3 (41·3-95·7)
61·6 (16·3-89·4)
83·5 (71·0-119·6)

65·3% (50·5-89·4)
82·7% (63·5-91·7)
55·1% (38·4-74·1)
67·9% (39·4-85·6)
67·1% (48·2-83·2)
49·1% (37·4-66·3)
47·8% (27·5-62·3)
58·3% (20·5-89·9)
62·3% (37·2-76·7)
43·9% (26·0-85·2)
62·1% (30·2-80·8)
53·6% (39·8-78·3)
76·0% (49·7-90·4)
66·4% (45·6-90·6)
62·1% (48·4-68·9)
60·3% (40·1-90·1)
84·0% (59·2-89·9)
55·4% (31·7-66·9)
58·2% (36·6-73·3)
46·8% (33·4-67·4)
66·8% (57·4-76·4)
64·3% (33·5-85·8)
49·6% (36·7-68·7)
72·1% (46·1-93·8)
61·3% (38·4-82·2)
55·7% (16·2-77·0)
73·4% (63·0-95·3)

4·5% (3·0-5·8)
7·6% (6·2-10·5)
20·2% (13·7-29·1)
1·6% (1·1-2·9)
3·6% (2·7-5·0)
5·8% (4·0-7·7)
5·1% (3·8-9·0)
1·7% (0·9-4·4)
6·5% (5·0-11·3)
35·4% (16·2-55·1)
1·4% (0·9-2·9)
9·4% (5·7-12·6)
4·4% (3·4-6·7)
3·6% (2·5-5·1)
16·7% (14·7-21·2)
2·6% (1·6-3·9)
2·4% (2·1-3·6)
3·4% (2·5-5·9)
2·0% (1·4-3·1)
10·1% (6·6-14·1)
4·6% (3·9-5·4)
2·5% (1·7-5·0)
4·0% (2·6-5·3)
0·9% (0·6-1·4)
4·5% (3·0-7·0)
3·1% (1·8-9·9)
3·3% (2·3-3·8)

1·1% (0·8-1·8)

0·6% (0·3-1·0)

1·4% (1·1-1·9)

0·3% (0·2-0·4)

1·9% (1·6-2·5)

0·4% (0·3-0·6)

1·2% (0·9-1·8)

0·2% (0·1-0·4)

1·3% (1·0-2·0)

0·5% (0·3-0·9)

1·5% (1·2-2·2)

0·7% (0·4-1·2)

1·2% (0·9-1·7)

0·5% (0·3-0·8)

1·1% (0·8-1·8)

0·3% (0·1-0·9)

1·3% (1·0-2·0)

0·5% (0·3-0·9)

2·0% (1·6-2·5)

0·7% (0·3-1·1)

1·1% (0·8-1·7)

0·3% (0·2-0·7)

1·4% (1·1-2·0)

0·8% (0·3-1·3)

1·3% (0·9-1·9)

0·5% (0·3-0·9)

1·0% (0·7-1·6)

0·3% (0·2-0·5)

1·2% (0·9-1·7)

0·3% (0·2-0·4)

1·1% (0·8-1·6)

0·4% (0·2-0·6)

1·3% (0·9-2·0)

0·3% (0·2-0·4)

1·6% (1·3-2·3)

0·6% (0·4-1·2)

1·1% (0·8-1·6)

0·2% (0·1-0·4)

1·3% (1·0-1·8)

0·3% (0·1-0·4)

1·7% (1·3-2·4)

0·4% (0·2-0·5)

1·3% (1·0-1·8)

0·2% (0·1-0·4)

1·2% (0·9-1·8)

0·4% (0·2-0·6)

1·0% (0·7-1·6)

0·2% (0·1-0·4)

1·3% (1·0-1·9)

0·7% (0·4-1·2)

1·4% (1·0-1·9)

0·4% (0·2-1·2)

1·1% (0·8-1·7)

0·4% (0·2-0·6)

(Table continues on next page)

2370

www.thelancet.com Vol 399 June 25, 2022

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Pakistan

561000 (323000-823000)

Azad Jammu & Kashmir

11000 (6820-15800)

Balochistan

15000 (7900-23700)

Gilgit-Baltistan

4350 (2340-6720)

Islamabad Capital Territory

3190 (2190-4260)

Khyber Pakhtunkhwa

157000 (75100-255000)

Punjab

265000 (163000-384000)

Sindh

105000 (69800-147000)

Southeast Asia, east Asia, and Oceania

1060000 (723000-1660000)

East Asia

16200 (8820-23300)

China

14700 (7490-21900)

North Korea

593 (417-957)

Taiwan (province of China)

845 (845-845)

Oceania

11600 (6280-19300)

Fiji

1300

(832-2140)

Guam

295 (259-439)

Northern Mariana Islands

7 (4-10)

Papua New Guinea

9920 (5200-17100)

Vanuatu

36 (13-69)

Southeast Asia

1030000 (702000-1630000)

Cambodia

14300 (9720-21700)

Indonesia

639000 (410000-1090000)

Laos

1090

(669-1680)

Malaysia

40700 (30600-59300)

Maldives

270 (247-362)

Mauritius

269 (266-292)

Myanmar

85900 (53500-140000)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

250·5 (144·2-367·5)
253·0 (157·3-365·1)
111·7 (59·0-176·5)
195·5 (105·1-301·7)
148·2 (101·7-197·5)
412·1 (197·1-669·6)
233·0 (143·1-336·6)
211·0 (139·8-294·2)
48·9 (33·5-77·0)
1·1 (0·6-1·6)
1·0 (0·5-1·5)
2·3 (1·6-3·6)
3·6 (3·6-3·6)
87·1 (47·3-145·3)
143·1 (91·3-234·7)
172·6 (151·8-257·1)
16·3 (10·6-22·7)
100·6 (52·7-173·1)
12·1 (4·4-23·6)
152·5 (104·1-242·4)
86·1 (58·5-130·4)
246·2 (158·2-419·2)
15·2 (9·3-23·4)
130·0 (97·7-189·3)
54·2 (49·5-72·6)
21·1 (20·8-22·9)
157·1 (97·8-256·3)

176000000 (128000000-219000000)
3510000 (2390000-4730000)
8310000 (3620000-12300000)
1740000 (1030000-2070000)
1260000 (652000-1800000)
39500000 (26400000-46800000)
75500000 (43100000-104000000)
45900000 (29100000-55000000)
281000000 (181000000-382000000)
2630000 (1470000-4790000)
2460000 (1340000-4550000)
76100 (49800-128000)
99700 (65100-166000)
4540000 (2310000-6970000)
307000 (149000-457000)
83900 (56500-120000)
3010 (1960-4490)
4150000 (1960000-6510000)
2950 (1080-6660)
274000000 (175000000-372000000)
3700000 (1630000-5720000)
161000000 (97100000-229000000)
1250000 (583000-2070000)
10200000 (6780000-14300000)
187000 (140000-324000)
181000 (117000-265000)
17800000 (9630000-25300000)

78·4 (57·1-97·5)
80·9 (55·1-109·1)
62·0 (27·1-91·8)
78·1 (46·4-92·9)
58·7 (30·3-83·4)
103·6 (69·4-122·9)
66·3 (37·8-91·1)
92·0 (58·3-110·3)
13·0 (8·4-17·7)
0·2 (0·1-0·3)
0·2 (0·1-0·3)
0·3 (0·2-0·5)
0·4 (0·3-0·7)
34·2 (17·4-52·5)
33·7 (16·4-50·2)
49·2 (33·1-70·4)
7·1 (4·6-10·6)
42·0 (19·9-66·0)
1·0 (0·4-2·3)
40·7 (25·9-55·3)
22·3 (9·8-34·4)
62·1 (37·4-88·4)
17·5 (8·1-28·9)
32·4 (21·7-45·8)
37·5 (28·1-65·0)
14·2 (9·2-20·7)
32·6 (17·6-46·3)

68·3% (51·6-81·5)
71·4% (51·9-90·9)
57·3% (26·7-80·5)
78·1% (46·4-92·9)
53·9% (29·2-72·4)
84·9% (63·0-91·9)
59·8% (35·9-79·3)
77·9% (53·4-89·1)
12·1% (8·0-15·9)
0·2% (0·1-0·3)
0·2% (0·1-0·3)
0·3% (0·2-0·5)
0·4% (0·3-0·7)
32·1% (16·8-47·4)
32·8% (16·3-48·0)
45·3% (30·5-62·9)
1·2% (0·3-2·7)
39·3% (19·4-59·0)
0·8% (0·3-2·1)
37·7% (24·8-49·7)
21·7% (9·7-32·8)
56·6% (35·4-76·2)
17·1% (8·0-28·1)
31·7% (21·4-44·2)
35·4% (26·8-58·3)
14·1% (9·1-20·5)
31·4% (17·2-43·8)

0·7% (0·6-1·0)
1·0% (0·7-1·4)
0·4% (0·3-0·9)
0·6% (0·5-1·0)
9·1% (6·0-16·5)
0·5% (0·4-0·7)
0·6% (0·4-1·0)
1·1% (0·9-1·6)
5·4% (3·8-8·1)
5·6% (2·8-9·2)
5·3% (2·5-8·8)
1·5% (1·1-1·9)
17·7% (10·0-25·4)
2·6% (1·5-4·6)
18·6% (11·5-35·1)
23·9% (15·9-33·9)
21·1% (13·6-30·7)
0·9% (0·5-1·8)
0·3% (0·1-0·5)
5·5% (3·9-8·3)
3·6% (2·1-7·4)
2·8% (1·9-4·4)
6·3% (3·2-11·4)
26·6% (18·2-38·5)
51·3% (28·1-65·1)
31·4% (19·9-45·8)
3·1% (2·1-5·4)

0·8% (0·6-1·3)

0·3% (0·2-0·5)

1·1% (0·8-1·6)

0·3% (0·2-0·5)

0·6% (0·4-1·0)

0·2% (0·1-0·5)

0·6% (0·4-1·0)

0·3% (0·1-0·5)

1·1% (0·7-2·1)

0·3% (0·2-0·5)

0·7% (0·4-1·2)

0·4% (0·2-0·7)

0·9% (0·7-1·5)

0·4% (0·2-0·6)

0·8% (0·6-1·2)

0·2% (0·1-0·4)

1·4% (1·1-2·0)

0·4% (0·3-0·6)

0·2% (0·1-0·4)

0·7% (0·3-1·0)

0·2% (0·1-0·4)

0·6% (0·3-1·0)

2·1% (1·6-2·8)

0·8% (0·6-1·0)

4·5% (3·7-5·2)

0·9% (0·5-1·3)

0·9% (0·6-1·5)

0·3% (0·2-0·6)

1·4% (1·1-2·1)

0·5% (0·3-1·0)

1·8% (1·5-2·2)

0·4% (0·2-0·5)

0·0% (0·0-0·0)

0·3% (0·1-0·4)

0·9% (0·6-1·4)

0·3% (0·1-0·6)

0·7% (0·5-1·2)

1·5% (0·5-4·2)

1·4% (1·1-2·0)

0·4% (0·3-0·6)

1·0% (0·8-1·5)

0·4% (0·3-1·0)

1·4% (1·1-2·0)

0·4% (0·3-0·7)

1·0% (0·7-1·5)

0·2% (0·1-0·5)

1·7% (1·4-2·0)

0·4% (0·3-0·6)

1·3% (1·1-1·5)

0·2% (0·1-0·2)

2·0% (1·6-2·4)

0·4% (0·2-0·6)

1·4% (1·0-2·1)

0·5% (0·3-0·9)

(Table continues on next page)

www.thelancet.com Vol 399 June 25, 2022

2371

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Philippines

158000 (111000-236000)

Seychelles

121 (120-122)

Sri Lanka

14000 (14000-14100)

Thailand

28300 (21600-36900)

Timor-Leste

1120 (741-1730)

Vietnam

45200 (28100-69600)

Sub-Saharan Africa

1750000 (1100000-2560000)

Central sub-Saharan Africa 161000 (95900-244000)

Angola

53200 (32100-80800)

Central African Republic

12000

(6660-21300)

Congo (Brazzaville)

8880 (5780-13400)

DR Congo

81100 (48400-133000)

Equatorial Guinea

2280 (1510-3600)

Gabon

3170 (2120-4420)

Eastern sub-Saharan Africa

827000 (509000-1300000)

Burundi

4080 (2580-6320)

Comoros

1200 (743-1760)

Djibouti

3250 (2070-4690)

Eritrea

4110 (2490-6280)

Ethiopia

170000 (99100-273000)

Kenya

145000 (88500-244000)

Madagascar

52400 (32400-87200)

Malawi

45700 (29500-70800)

Mozambique

63900 (41000-88500)

Rwanda

18600 (12500-26800)

Somalia

75400 (36900-143000)

South Sudan

12400 (6520-20300)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

140·5 (99·3-210·2)
118·3 (117·6-119·7)
64·1 (64·0-64·6)
40·3 (30·8-52·7)
84·1 (55·5-129·7)
46·9 (29·1-72·2)
162·6 (102·0-237·8)
122·2 (72·9-185·3)
176·6 (106·5-267·9)
226·6 (125·8-401·2)
168·7 (109·7-254·2)
92·5 (55·2-151·9)
160·6 (106·3-253·3)
181·4 (121·3-252·8)
200·8 (123·5-316·2)
34·2 (21·6-52·9)
168·0 (104·1-246·6)
270·2 (172·3-389·6)
61·3 (37·1-93·6)
158·2 (92·1-253·5)
288·1 (176·3-486·4)
196·4 (121·3-326·6)
247·9 (160·0-383·8)
216·4 (138·9-299·8)
146·4 (98·5-211·5)
370·6 (181·3-702·7)
133·4 (70·3-218·4)

59200000 (36900000-84800000)
52600 (41700-60500)
3400000 (2520000-4460000)
8100000 (4370000-12800000)
410000 (209000-619000)
8460000 (4760000-14900000)
855000000 (744000000-932000000)
117000000 (76100000-138000000)
30000000 (15300000-37000000)
3640000 (2620000-5330000)
4330000 (3090000-5270000)
76900000 (46300000-91000000)
1100000 (797000-1340000)
1300000 (652000-1870000)
344000000 (304000000-378000000)
1850000 (1360000-2400000)
479000 (362000-606000)
770000 (450000-1180000)
1910000 (1430000-2490000)
105000000 (81900000-124000000)
50700000 (40700000-57600000)
23400000 (18500000-29000000)
17000000 (11100000-19100000)
30300000 (23000000-33500000)
5980000 (3350000-9270000)
19500000 (15700000-23700000)
5620000 (3370000-9350000)

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

52·8 (32·9-75·6)
51·5 (40·9-59·3)
15·6 (11·5-20·4)
11·6 (6·2-18·3)
30·7 (15·7-46·4)
8·8 (4·9-15·4)
79·3 (69·0-86·4)
89·2 (57·9-104·6)
99·7 (50·8-122·9)
68·7 (49·4-100·6)
82·2 (58·7-100·0)
87·7 (52·8-103·8)
77·4 (56·1-94·2)
74·5 (37·3-107·1)
83·5 (73·7-91·9)
15·5 (11·4-20·1)
67·0 (50·7-84·9)
64·0 (37·4-98·4)
28·4 (21·3-37·1)
97·8 (76·1-115·0)
101·0 (81·1-114·6)
87·7 (69·3-108·7)
92·4 (60·0-103·5)
102·6 (77·8-113·4)
47·1 (26·4-73·1)
95·8 (77·4-116·7)
60·6 (36·3-100·7)

48·6% (31·3-66·6)
45·8% (37·6-51·1)
15·3% (11·4-19·9)
11·4% (6·2-18·0)
29·6% (15·3-43·8)
8·7% (4·9-15·3)
70·5% (61·6-75·9)
76·3% (52·8-86·1)
84·0% (47·5-95·8)
61·9% (46·2-84·0)
71·7% (53·3-85·9)
75·1% (48·5-86·0)
70·2% (53·6-83·6)
65·5% (35·9-86·5)
72·9% (64·3-79·2)
15·3% (11·3-19·8)
67·0% (50·7-84·8)
58·2% (35·5-84·3)
27·7% (20·8-36·1)
83·2% (67·9-90·9)
84·1% (71·6-92·3)
75·5% (63·0-90·2)
86·7% (57·3-94·4)
89·3% (68·9-98·1)
44·2% (25·4-66·0)
80·5% (68·4-90·0)
56·5% (35·5-88·4)

5·1% (3·3-7·7)
44·3% (38·3-55·4)
17·0% (12·6-22·3)
28·3% (16·3-47·9)
5·3% (3·2-9·5)
15·1% (8·1-25·1)
0·7% (0·7-0·8)
0·2% (0·1-0·3)
0·2% (0·2-0·4)
0·3% (0·2-0·4)
0·4% (0·4-0·6)
0·1% (0·1-0·1)
1·2% (1·0-1·7)
3·1% (2·0-5·7)
0·5% (0·4-0·5)
1·1% (0·8-1·5)
0·9% (0·7-1·2)
1·8% (1·1-3·0)
0·4% (0·3-0·5)
0·4% (0·3-0·5)
0·5% (0·4-0·6)
0·2% (0·2-0·2)
0·4% (0·3-0·6)
0·5% (0·5-0·7)
1·8% (1·1-3·0)
0·1% (0·1-0·1)
0·2% (0·1-0·4)

1·2% (0·9-1·7)

0·3% (0·2-0·5)

1·5% (1·3-1·9)

0·2% (0·2-0·3)

2·0% (1·7-2·4)

0·4% (0·3-0·6)

2·7% (2·2-3·2)

0·4% (0·2-0·7)

0·9% (0·6-1·3)

0·3% (0·2-0·5)

1·9% (1·5-2·4)

0·7% (0·4-1·0)

0·6% (0·4-0·9)

0·2% (0·1-0·3)

0·5% (0·4-0·9)

0·1% (0·1-0·2)

0·5% (0·4-0·8)

0·2% (0·1-0·4)

0·4% (0·3-0·9)

0·3% (0·2-0·6)

0·5% (0·4-0·9)

0·2% (0·1-0·4)

0·5% (0·3-0·9)

0·1% (0·1-0·2)

0·5% (0·4-0·8)

0·2% (0·1-0·4)

0·7% (0·6-1·1)

0·3% (0·2-0·6)

0·5% (0·4-0·9)

0·2% (0·1-0·4)

0·5% (0·3-0·9)

0·2% (0·1-0·4)

0·6% (0·5-1·1)

0·3% (0·2-0·4)

0·7% (0·5-1·1)

0·4% (0·2-0·7)

0·6% (0·4-1·0)

0·3% (0·2-0·5)

0·5% (0·3-0·8)

0·2% (0·1-0·3)

0·6% (0·4-1·0)

0·3% (0·2-0·5)

0·5% (0·4-0·9)

0·2% (0·1-0·4)

0·6% (0·4-1·0)

0·3% (0·2-0·5)

0·5% (0·4-0·9)

0·2% (0·1-0·3)

0·6% (0·5-1·0)

0·3% (0·2-0·6)

0·4% (0·3-0·8)

0·4% (0·2-0·9)

0·4% (0·3-0·8)

0·2% (0·1-0·5)

(Table continues on next page)

2372

www.thelancet.com Vol 399 June 25, 2022

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

Tanzania

101000 (62300-165000)

Uganda

61200 (41600-92500)

Zambia

68400 (44600-113000)

Southern sub-Saharan Africa

378000 (273000-533000)

Botswana

14800 (10000-20900)

Eswatini

11300 (7440-17900)

Lesotho

15200 (9540-23900)

Namibia

15200 (10700-23200)

South Africa

257000 (190000-370000)

Zimbabwe

65000 (41400-93400)

Western sub-Saharan Africa

387000 (235000-548000)

Benin

7000 (4520-10500)

Burkina Faso

14400 (8450-23800)

Cape Verde

560 (421-801)

Cameroon

33400 (21300-49400)

Chad

12600

(6640-19700)

Côte d'Ivoire

28200 (16900-41700)

The Gambia

5370 (3490-7590)

Ghana

28300 (19600-38900)

Guinea

22500 (12800-37300)

Guinea-Bissau

3600 (2180-5130)

Liberia

6790 (4300-10100)

Mali

25300

(15500-36800)

Mauritania

6340 (3660-9250)

Niger

12900 (6910-19600)

Nigeria

133000 (68300-197000)

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

178·5 (109·9-290·8)
148·8 (101·2-224·9)
375·1 (244·8-618·7)
481·5 (347·5-678·1)
633·5 (428·8-893·6)
985·6 (651·5-1568·4)
725·6 (456·3-1140·9)
634·5 (444·4-963·9)
461·9 (341·4-664·9)
433·3 (276·1-622·0)
84·9 (51·5-120·1)
55·2 (35·7-82·7)
63·7 (37·2-104·7)
99·3 (74·7-142·2)
114·9 (73·1-169·7)
76·7 (40·5-120·2)
107·8 (64·4-159·2)
239·2 (155·5-338·0)
89·7 (62·2-123·3)
177·9 (101·6-294·9)
189·2 (114·6-270·0)
141·8 (89·7-210·9)
115·3 (70·6-168·0)
158·0 (91·3-230·5)
55·2 (29·7-83·9)
62·0 (31·8-91·9)

40700000 (33800000-45500000)
22700000 (16500000-30900000)
17700000 (12100000-20300000)
58200000 (47800000-67900000)
1600000 (749000-2300000)
866000 (451000-1280000)
1430000 (713000-2190000)
1720000 (1010000-2450000)
38600000 (30500000-46100000)
14000000 (6470000-16100000)
336000000 (270000000-387000000)
4260000 (2520000-6580000)
17100000 (11700000-22800000)
368000 (196000-508000)
20200000 (2570000-30400000)
9070000 (4990000-14600000)
20000000 (13900000-25200000)
1980000 (1300000-2580000)
21800000 (14800000-26700000)
11500000 (7760000-15100000)
1340000 (799000-2080000)
3230000 (2020000-4510000)
17500000 (10900000-22200000)
2970000 (1730000-4510000)
12600000 (6640000-18900000)
170000000 (126000000-217000000)

71·7 (59·5-80·3)
55·1 (40·2-75·1)
97·0 (66·2-111·1)
74·1 (60·8-86·4)
68·5 (32·0-98·5)
75·8 (39·5-112·3)
68·3 (34·1-104·8)
71·6 (41·8-102·1)
69·4 (54·9-82·9)
93·3 (43·1-107·4)
73·7 (59·2-84·8)
33·6 (19·9-52·0)
75·4 (51·7-100·3)
65·3 (34·8-90·2)
69·4 (8·8-104·5)
55·3 (30·4-88·8)
76·4 (53·0-96·1)
88·4 (58·0-114·7)
69·0 (46·8-84·5)
91·0 (61·4-119·3)
70·5 (42·0-109·7)
67·5 (42·1-94·2)
79·7 (49·6-101·2)
74·0 (43·2-112·3)
54·2 (28·5-81·0)
79·2 (58·5-101·2)

64·7% (55·1-71·5)
51·4% (37·6-69·5)
87·7% (60·8-98·7)
67·8% (56·3-77·3)
65·8% (31·4-94·8)
67·4% (38·0-94·3)
61·9% (32·1-90·9)
66·4% (39·9-93·7)
64·0% (50·8-75·1)
83·1% (40·9-95·6)
67·0% (55·5-77·2)
32·2% (19·5-49·0)
68·5% (49·1-86·7)
65·2% (34·6-90·1)
61·8% (8·8-86·8)
54·0% (30·0-85·6)
68·2% (49·4-80·7)
75·2% (53·2-89·8)
62·3% (44·1-75·0)
77·5% (57·5-91·6)
65·3% (41·4-87·7)
60·8% (39·9-80·5)
75·0% (48·2-93·3)
67·6% (41·8-90·7)
51·0% (28·0-72·3)
72·3% (55·1-88·5)

0·4% (0·3-0·5)
0·6% (0·4-0·8)
1·2% (1·0-1·7)
6·1% (5·1-7·3)
13·6% (8·4-25·9)
5·8% (3·6-10·3)
1·7% (1·0-3·0)
7·9% (5·3-12·8)
7·8% (6·4-9·7)
1·0% (0·8-2·1)
0·2% (0·2-0·3)
0·6% (0·4-1·0)
0·1% (0·1-0·1)
11·1% (7·5-19·5)
0·9% (0·3-4·2)
0·1% (0·0-0·1)
0·3% (0·2-0·4)
0·5% (0·4-0·8)
0·6% (0·5-0·9)
0·3% (0·2-0·4)
0·5% (0·3-0·8)
0·2% (0·1-0·3)
0·1% (0·1-0·2)
1·4% (0·9-2·2)
0·1% (0·0-0·1)
0·1% (0·1-0·2)

0·6% (0·5-1·0)

0·3% (0·2-0·4)

0·5% (0·4-0·9)

0·3% (0·2-0·4)

0·6% (0·5-1·0)

0·4% (0·2-0·7)

1·0% (0·8-1·2)

0·7% (0·5-1·0)

0·9% (0·7-1·2)

1·0% (0·5-2·3)

0·7% (0·5-0·9)

1·4% (0·8-2·7)

0·8% (0·6-1·0)

1·2% (0·6-2·9)

0·9% (0·7-1·2)

0·9% (0·6-1·7)

1·1% (0·9-1·4)

0·7% (0·5-1·1)

0·7% (0·5-0·9)

0·5% (0·3-1·0)

0·5% (0·4-0·9)

0·1% (0·1-0·2)

0·5% (0·4-0·9)

0·2% (0·1-0·3)

0·5% (0·4-0·8)

0·1% (0·1-0·2)

1·0% (0·8-1·4)

0·2% (0·1-0·3)

0·5% (0·4-0·8)

0·3% (0·1-1·5)

0·4% (0·3-0·7)

0·2% (0·1-0·3)

0·5% (0·4-0·9)

0·1% (0·1-0·2)

0·5% (0·4-0·9)

0·3% (0·2-0·4)

0·7% (0·5-1·1)

0·1% (0·1-0·2)

0·5% (0·4-0·9)

0·2% (0·1-0·4)

0·5% (0·3-0·8)

0·3% (0·2-0·6)

0·6% (0·5-1·0)

0·2% (0·1-0·4)

0·5% (0·4-0·8)

0·2% (0·1-0·3)

0·7% (0·5-1·0)

0·2% (0·1-0·4)

0·4% (0·3-0·7)

0·1% (0·1-0·3)

0·5% (0·4-0·8)

0·1% (0·0-0·1)

(Table continues on next page)

www.thelancet.com Vol 399 June 25, 2022

2373

Articles

Cumulative total COVID-19 deaths

(Continued from previous page)

São Tomé and Príncipe

201 (132-284)

Senegal

32900 (21100-50700)

Sierra Leone

6330 (4070-9140)

Togo

7490

(4910-10900)

Data are estimates (95% uncertainty interval).

Cumulative total COVID-19 death rate (per 100000 population)

Cumulative infections

98·1 (64·0-138·4)
217·4 (139·7-334·9)
76·4 (49·2-110·3)
94·5 (62·0-138·1)

109000 (82700-137000)
13800000 (10700000-16500000)
3520000 (2160000-4930000)
4690000 (3220000-6130000)

Cumulative infection rate (per 100 population)

Cumulative percentage infected

Cumulative infection- detection ratio

Cumulative infection- hospitalisation ratio

Cumulative infection- fatality ratio

52·9 (40·3-66·9)
91·2 (70·5-108·8)
42·5 (26·1-59·5)
59·3 (40·7-77·4)

52·9% (40·2-66·8)
78·3% (65·1-87·4)
40·5% (25·5-55·3)
53·9% (38·5-68·7)

3·4% (2·6-4·4)
0·5% (0·4-0·7)
0·2% (0·1-0·3)
0·6% (0·4-0·8)

0·5% (0·4-0·9)
0·5% (0·4-0·9)
0·5% (0·4-0·9)
0·6% (0·4-1·0)

0·2% (0·1-0·3)
0·2% (0·2-0·4)
0·2% (0·1-0·3)
0·2% (0·1-0·3)

Table: Cumulative total COVID-19 deaths, infections, proportion of the population infected, infection-detection ratio, infection-hospitalisation ratio, and infection-fatality ratio up to Nov 14, 2021, by location

<10% 10 to <20% 20 to <30% 30 to <40% 40 to <50% 50 to <60% 60 to <70% 70 to <80% 80%

Figure 3: Cumulative proportion of the population infected with SARS-CoV-2 at least once by Nov 14, 2021, by country and territory The first administrative level is mapped for countries that are modelled at that level and have a population greater than 100 million.

The proportion of the population effectively vaccinated is a function of doses administered and brand-specific efficacy and is discounted for existing natural immunity at the time of delivery.
Role of the funding source The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or the writing of the report.
Results
Globally, daily SARS-CoV-2 infections steadily increased over the first several months of the pandemic, surpassing 3 million daily infections for the first time in mid-April, 2020, and then doubling to 6 million per day 6 weeks later (figure 2A). Global daily infections remained higher than 5 million per day until dipping slightly below that threshold after a period of decline in

January and February, 2021. Driven primarily by the delta variant surge in India, global daily infections soared to a pandemic high of nearly 17 million in April, 2021, then dropped as low as 6 million by June, 2021, before delta variant waves in other parts of the world led to another global surge peaking at over 8 million infections per day in July, 2021. This peak was followed by the longest sustained decline of the pandemic at the global level, wherein global infections dropped below 3 million per day by the end of October, 2021, for the first time in 18 months. Between the start of the pandemic and Nov 14, 2021, there were an estimated 3·80 billion (95% uncertainty interval [UI] 3·44-4·08) SARS-CoV-2 infections and reinfections globally (table, figure 2B). Nearly 1·5 billion of these infections occurred in south Asia (1·34 billion [1·20-1·49]), the most infections of all seven super-regions, whereas the highest infection rate was estimated in sub-Saharan Africa (79·3 per

2374

www.thelancet.com Vol 399 June 25, 2022

Articles

100 population [95% UI 69·0-86·4]). Four other super-

regions each had infection rates greater than 60 per

2·00

100 population (table): central Europe, eastern Europe,

and central Asia (78·4 [49·3-93·2]); south Asia (74·3

1·75

[66·5-82·6]); Latin America and the Caribbean (64·1

1·50

[57·2-71·3]); and north Africa and the Middle East (62·7

[46·2-79·0]). Southeast Asia, east Asia, and Oceania had

1·25

effective R

the lowest infection rate (13·0 per 100 population

[8·4-17·7]) of all seven super-regions, whereas the high-

1·00

income super-region had nearly double that infection

rate but the fewest infections (239 million [95% UI

0·75

226-252]; table). At the global level, the cumulative

0·50

proportion of the population infected with SARS-CoV-2

one or more times reached 13·7% (95% UI 12·2-15·1) by

0·25

the end of the first wave of global infections on Oct 1, 2020,

increasing to 24·1% (21·9-25·8) by the end of the second

wave on Feb 15, 2021. More than a third of the global

2·00

population had been exposed to COVID-19 after the delta

variant surge in India (35·0% [32·2-37·3]). And by

1·75

Nov 14, 2021, 43·9% (39·9-46·9) of the global population

1·50

(3·39 billion individuals [3·08-3·63]) had been infected

with SARS-CoV-2 at least once. The cumulative proportion

1·25

effective R

infected at least once varied greatly across countries and

territories (table, figure 3). Over 70% of the population

1·00

had been infected in 40 countries, including over 80% in

17 countries and across states in Mexico, India, and

0·75

Pakistan. More than half the population had been infected

0·50

in an additional 55 countries and territories across every

super-region, except high income. Notable cross-border

0·25

variations were observed in some parts of the world, such as at the interface of western and central Europe, where the percentage of the population infected was substantially

0

10

20

30

40

50

60

70

80

Total immunity (%)

lower in Germany, Austria, and Italy than in the bordering Figure 4: Reffective by total immunity

nations Poland, Czechia, Slovakia, Hungary, and Slovenia. Proportion of total immunity shown starting at 1%. Reffective=effective reproductive number.

In South America, a clear demarcation can be seen

splitting the tropical and Andean nations from the New Zealand and China to 1125 (724-1709) in Bolivia.

southern nations and the Brazilian state Rio Grande do Sul. Death rates over 450 per 100000 were estimated in

Countries in mainland southeast Asia such as Laos, 23 countries, as well as many states in Mexico; multiple

Thailand, and Vietnam, maintained a much lower states in Brazil, Italy, and the USA; and one in India. At

percentage of population infected than neighbouring least one country in every super-region except southeast

south Asian countries or island nations within the region, Asia, east Asia, and Oceania surpassed 300 estimated

such as Indonesia and the Philippines. The cumulative deaths per 100000, 51 in total. Estimated death rates

percentage of population infected varied widely within remained very low throughout much of east and

most countries for which subnational units were southeast Asia, high-income Asia Pacific, Australasia,

modelled in this analysis, varying by a factor of two across and select countries such as Norway, Iceland, and Qatar.

administrative units in Brazil, India, Italy, and Mexico; a Posterior estimates of the IDR showed that 44·6%

factor of three in Germany and Spain; and over a (95% UI 42·3-47·2) of COVID-19 infections were detected

factor of four in the USA (table).

in the high-income super-region, with 18 countries and

Cumulative total COVID-19 deaths and death rates on parts of Canada, Italy, Spain, and the USA detecting over

Nov 14, 2021, can be found in the table and appendix 1 half of the COVID-19 infections that occurred in those

(section 9.4). Although roughly 5·6 million deaths due locations by Nov 14, 2021. Countries in Latin America and

to COVID-19 had been reported by this date, estimated the Caribbean and central Europe, eastern Europe, and

total deaths attributable to COVID-19 were nearly three central Asia detected about 10% of infections on average,

times as high at 15·1 million (95% UI 11·2-20·2)--a and fewer than 10% of infections were identified in each

rate of 195 deaths per 100000 people (145-262). Across of the remaining four super-regions (table). The IHR

all countries and territories, the estimated death rate varied by a factor of four across super-regions, and the IFR

ranged from no more than 1 per 100000 people in by a factor of five. The highest IHR and IFR were

www.thelancet.com Vol 399 June 25, 2022

2375

Articles

estimated primarily in countries with older population structures, such as Japan. The lowest IDR, IHR, and IFR were all detected in sub-Saharan Africa, where only the southern region exceeded 0·5% for any ratio (table).
During the first 20 months of the pandemic, Reffective varied widely across locations and time, from lower than 0·1 to higher than 2·0. Only 39% of location-weeks for which total immunity was under 10% had Reffective lower than 1. Between 10% and 20% total immunity, this proportion increased to 56%, and between 20% and 30% total immunity, we observed an additional increase to 65% of location-weeks with an Reffective lower than 1 (figure 4). However, over the range of 30-60% total immunity, the percentage of observations with Reffective lower than 1 decreased back to 55%. This absence of a clear relationship highlights the many other factors such as seasonality, physical distancing mandates, mask use, and new variant spread that have influenced Reffective over time. From 60% to 70% total immunity, we observed 60% of observations with Reffective lower than 1, and above 70% total immunity, 72% of location-weeks had an Reffective lower than 1. Although these data suggest transmission to be somewhat lower at the highest levels of total immunity observed thus far, even with total immunity at 80%, we saw no indication of an abrupt drop in R . effective
Discussion
In this study, we estimated that global daily SARS-CoV-2 infections fluctuated between 3 million and 17 million new cases per day from April, 2020, to October, 2021. In total, we estimated that between the start of the pandemic and Nov 14, 2021, there were 3·80 billion (95% UI 3·44-4·08) total SARS-CoV-2 infections and reinfections combined and that 3·39 billion (3·08-3·63) individuals had been infected with SARS-CoV-2 one or more times. The proportion of the population that had been infected at least once ranged from under 1% to over 80% across countries and territories. The highest cumulative infection rates were estimated in sub-Saharan Africa; central Europe, eastern Europe, and central Asia; and south Asia. Translating daily infections into Reffective showed no clear herd immunity threshold.
Cumulative infection rates through Nov 14, 2021, varied greatly across countries and territories and between subnational units within countries. This variation can be explained by a combination of factors including policies enacted by governments to encourage mask use and reduce social interaction,48-50 presence of escape variants, testing and contact tracing capacity,51,52 previous exposure to other coronaviruses,53 baseline patterns of social interaction, and more. For instance, greatly different levels of cumulative infection were found in some neighbouri­ng countries with similar patterns of non-COVID-19 disease burden, such as Norway and Sweden.43 In these two countries, testing and contact tracing strategies, government restrictions,

and mobility patterns varied substantially,54 contributing to substantially different SARS-CoV-2 infection outcomes. Other countries, such as Australia and New Zealand, have shown how early and effective lockdowns, combined with geographical isolation and travel restrictions, have kept transmission low throughout the study period.18,55,56 Excess mortality and seroprevalence data available suggest that some of the most severe COVID-19 epidemics occurred in eastern Europe and central Asia. This might be related to comparatively less public intervention, such as mask mandates or stay-at-home orders.57,58 But, although it might be tempting to ascribe all variations in cumulative infections to effective public health action in different countries, the April-September, 2021, surges in many southeast Asian countries where, up to the end of March, public health responses to the pandemic had been swift and believed to be effective,59-61 suggest that other factors might also be contributing to these patterns.57,58
The empirical measurements of the IDR suggest that it was low early in the pandemic, when testing was scarce, and increased as testing capacity expanded. On average, the IDR increased steadily, especially over the course of the first year of the pandemic, but with marked variation across countries. This variation highlights how analyses based on the assumption that SARS-CoV-2 IDR is constant across location and time7 could be very misleading. Although we expect that, in general, IDR increased as testing capacity increased, national guidance on who should be tested, and changes in that guidance over the course of the pandemic, might also affect the IDR. For example, on May 1, 2021, the CDC issued guidance not to test vaccinated individuals who had been exposed to COVID-19 but did not have symptoms.62 Likewise, the advent of workplace and school testing programmes in the later months of 2021 might also shift the IDR up in some countries. Great care needs to be taken when interpreting trends based only on reported cases in the later phases of the pandemic. In many settings, hospitalisations--which tend to be a robust measure of more severe disease--are likely to be more informative than confirmed infections.
Our analysis suggests that the cumulative IFR across countries and territories ranged from 0·1% to 2·0% as of Nov 14, 2021. Age standardisation has been shown to explain a considerable portion of this variation,40 but substantial differences remain in the available data. Some of this variation appears to be due to the prevalence of certain comorbidites,63 and some could be residual errors in the estimation of excess mortality or seroprevalence in the available data. Nevertheless, it might turn out that other factors, such as previous exposure to other coronaviruses, help explain the considerable variation in the age-standardised IFR that is observed in the data. Such variation in the IFR should caution against studies that assume the IFR (either all-age or age-standardised) is constant across locations and over time. The temporal

2376

www.thelancet.com Vol 399 June 25, 2022

Articles

analysis of the IFR supports the clinical observation that the IFR was initially much higher in March and April, 2020, and subsequently declined as clinical practice improved, particularly in approaches to oxygenation and the use of corticosteroids.64-67 Trials of some oral antivirals have shown substantial effectiveness in preventing severe disease and death, suggesting that the IFR might decline further in the coming months if these and other antivirals become widely available and if diagnostic capacity is able to support early treatment.68,69
We did not find a clear relationship between Reffective and total immunity up to 60%. Over 60%, Reffective was more often under 1·0 than over 1·0. Despite this finding, we observed no obvious herd immunity threshold in the data. The generally weak relationship between Reffective and the total immunity highlights the powerful role of other factors driving infection, including physical distancing mandates, seasonality, mask use, and the emergence of new variants over the study period (especially the delta variant) in mediating this relationship. Although figure 4 does not show us the prospects for reaching herd immunity in each location for any given season or variant, the overall relationship points to the very high degree of combined natural and vaccine-derived immunity that might be needed to block community transmission (especially in the winter months).
This empirical analysis has several important limitations. First, some seroprevalence surveys (such as the CDC monitoring of laboratory data) might be biased, but the direction of the bias is difficult to ascertain. Additionally, in reporting serosurveys, various corrections can be applied to produce estimates, including the use of sampling weights, correcting for manufacturing sensitivity and specificity, or, in some instances, full correction for waning detectability. Where possible, we attempted to standardise for this by extracting data that were adjusted for sampling frame and manufacturing sensitivity, but not more complex corrections. If this was not possible, we used the raw numerator and denominator as reported. In some instances, no metadata were provided to describe whether any correction had been applied. In all instances, these values were treated as equivalent. Second, we have assumed that one of the key covariates for the IDR is demonstrated testing capacity. By construction, this variable cannot decline as it is the maximum value of previously observed daily testing rates. In some countries, changes in guidance on who gets tested could lead to declines in effective testing and the IDR, and we may have missed these changes. The CDC guidance in spring, 2021, not to test vaccinated individuals who were asymptomatic or mildly symptom­ atic is an example of such a policy. Third, vaccination increases the proportion of the population who test positive on antispike antibody tests. We note in some locations, particularly in the UK, attempts to account for vaccination rates resulted in decreasing estimates of seroprevalence over time, suggesting that assumptions about the probability of vaccinated individuals being identified in serological

surveys in those locations are incompatible with the data collected; in these instances, we excluded the seroprevalence data from the analysis. Fourth, matched seroprevalence surveys with reported cumulative cases, hospitalisations, and deaths provide an interval measure of the IDR, IHR, and IFR from the beginning of the pandemic to the period of the survey. We used these interval measures to derive relationships for the daily IDR, IHR, and IFR. This approach decreases our ability to identify drivers of shorterterm fluctuations in these key rates. Fifth, the availability of hospital admissions data in low-income and middleincome settings was generally low, minimising its effect on the estimation process in many countries. Sixth, we used estimates of total COVID-19 mortality based on the measurement or estimation of excess mortality multiplied by a statistical estimate of the proportion of excess mortality directly attributable to infection with SARS-CoV-2. This statistical estimation was based on removing the effect of a low IDR and reduced mobility that might be a proxy for deferred care and other health effects of isolation. This estimate of the proportion of excess mortality that is total COVID-19 has wide UIs. Eventually, better data will emerge on causes of death during the pandemic that will hopefully refine the estimate of total COVID-19 deaths. The wide uncertainty in the ratio of total COVID-19 to reported COVID-19 is reflected in the uncertainty analysis in this study. Seventh, our model permitted a maximum of two infections per individual--in the case where a person gets an ancestral or alpha variant infection, they might also be infected with a beta, gamma, or delta variant. There is evidence of waning naturally derived immunity, suggesting that an individual might become more broadly susceptible to reinfection sometime after exposure.70
This empirical analysis of past COVID-19 infections ends at the point where the omicron (B.1.1.529) wave was first detected in Gauteng province in South Africa. Omicron is much more transmissible than previous variants and has shown immune escape.71 Since Nov 14, 2021, the omicron wave has taken off in all countries and territories. Because of much lower severity of disease, the IDR is likely to have dropped considerably during the omicron wave. Models suggest that more than 50% of the world might have been infected with omicron already--however, a detailed analysis will have to await new seroprevalence data emerging in the coming months. Cumulative infections for COVID-19 through to March, 2022, might be nearly double what occurred through Nov 14, 2021.
Conclusion COVID-19 has had a staggering impact on the world, with 3·39 billion (95% UI 3·08-3·63) people infected with SARS-CoV-2 at least once as of Nov 14, 2021. These findings highlight the potential for COVID-19 to have a continued and profound impact on the world's population. The vast differences in cumulative proportion of the population infected across countries and territories can

www.thelancet.com Vol 399 June 25, 2022

2377

Articles

For the latest estimates of daily infections see https://covid19. healthdata.org

help policy makers identify locations whose transmissionprevention strategies should be emulated, as well as those populations at greatest risk of future infection--a factor that should be considered in global vaccine prioritisation. Our statistical approach to estimating SARS-CoV-2 infection, which can be applied routinely and will allow for rapid availability of estimates, will be crucially important for research, science, and policy efforts towards pandemic preparedness, response, and control in the coming months and years. It has and continues to be made freely available to all on a routine basis.
COVID-19 Cumulative Infection Collaborators Ryan M Barber, Reed J D Sorensen, David M Pigott, Catherine Bisignano, Austin Carter, Joanne O Amlag, James K Collins, Cristiana Abbafati, Christopher Adolph, Adrien Allorant, Aleksandr Y Aravkin, Bree L Bang-Jensen, Emma Castro, Suman Chakrabarti, Rebecca M Cogen, Emily Combs, Haley Comfort, Kimberly Cooperrider, Xiaochen Dai, Farah Daoud, Amanda Deen, Lucas Earl, Megan Erickson, Samuel B Ewald, Alize J Ferrari, Abraham D Flaxman, Joseph Jon Frostad, Nancy Fullman, John R Giles, Gaorui Guo, Jiawei He, Monika Helak, Erin N Hulland, Bethany M Huntley, Alice Lazzar-Atwood, Kate E LeGrand, Stephen S Lim, Akiaja Lindstrom, Emily Linebarger, Rafael Lozano, Beatrice Magistro, Deborah Carvalho Malta, Johan Månsson, Ana M Mantilla Herrera, Ali H Mokdad, Lorenzo Monasta, Mohsen Naghavi, Shuhei Nomura, Christopher M Odell, Latera Tesfaye Olana, Samuel M Ostroff, Maja Pasovic, Spencer A Pease, Robert C Reiner Jr, Grace Reinke, Antonio Luiz P Ribeiro, Damian F Santomauro, Aleksei Sholokhov, Emma E Spurlock, Ruri Syailendrawati, Roman Topor-Madry, Anh Truc Vo, Theo Vos, Rebecca Walcott, Ally Walker, Kirsten E Wiens, Charles Shey Wiysonge, Nahom Alemseged Worku, Peng Zheng, Simon I Hay, Emmanuela Gakidou, Christopher J L Murray.
Affiliations Institute for Health Metrics and Evaluation (R M Barber BS, R J D Sorensen PhD, D M Pigott PhD, C Bisignano MPH, A Carter MPH, J O Amlag MPH, J K Collins BS, A Allorant PhD, A Y Aravkin PhD, B L Bang-Jensen MA, E Castro MS, S Chakrabarti MA, R M Cogen BA, E Combs BA, H Comfort MPH, K Cooperrider BA, X Dai PhD, F Daoud BS, A Deen MPH, L Earl MSc, M Erickson MA, S B Ewald MS, A J Ferrari PhD, A D Flaxman PhD, J J Frostad MPH, N Fullman MPH, J R Giles PhD, G Guo MPH, J He MSc, M Helak BA, E N Hulland MPH, B M Huntley BA, A Lazzar-Atwood BSc, K E LeGrand MPH, Prof S S Lim PhD, E Linebarger BA, Prof R Lozano MD, J Månsson MS, A H Mokdad PhD, Prof M Naghavi PhD, C M Odell MPP, S M Ostroff PhD, M Pasovic MEd, S A Pease BS, R C Reiner Jr PhD, G Reinke MA, D F Santomauro PhD, A Sholokhov MSc, E E Spurlock MPH, R Syailendrawati MA, A T Vo BSc, Prof T Vos PhD, A Walker MA, P Zheng PhD, Prof S I Hay DSc, Prof E Gakidou PhD, Prof C J L Murray DPhil), Department of Global Health (R J D Sorensen, S Chakrabarti, E N Hulland), Department of Health Metrics Sciences, School of Medicine (D M Pigott, A Y Aravkin, X Dai, A D Flaxman, Prof S S Lim, Prof R Lozano, A H Mokdad, Prof M Naghavi, R C Reiner Jr, Prof T Vos, P Zheng, Prof S I Hay, Prof E Gakidou, Prof C J L Murray), Department of Political Science (Prof C Adolph PhD), Center for Statistics and the Social Sciences (Prof C Adolph), Department of Applied Mathematics (A Y Aravkin), Henry M Jackson School of International Studies (S M Ostroff), Evans School of Public Policy & Governance (R Walcott MPH), University of Washington, Seattle, WA, USA; Department of Juridical and Economic Studies (C Abbafati PhD), La Sapienza University, Rome, Italy; School of Public Health (A J Ferrari, A Lindstrom MEpi, A M Mantilla Herrera PhD, D F Santomauro), The University of Queensland, Brisbane, QLD, Australia; School of Public Health (A Lindstrom), West Moreton Hospital Health Services (A M Mantilla Herrera), Policy and Epidemiology Group (D F Santomauro), Queensland Centre for Mental Health Research, Wacol, QLD, Australia; Munk School of Global Affairs and Public Policy (B Magistro PhD), University of Toronto, Toronto, ON, Canada;

Department of Maternal and Child Nursing and Public Health (Prof D C Malta PhD), Department of Internal Medicine (Prof A P Ribeiro MD), Centre of Telehealth (Prof A P Ribeiro), Federal University of Minas Gerais, Belo Horizonte, Brazil; Clinical Epidemiology and Public Health Research Unit (L Monasta DSc), Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy; Department of Health Policy and Management (S Nomura PhD), Keio University, Tokyo, Japan; Department of Global Health Policy (S Nomura), University of Tokyo, Tokyo, Japan; School of Electrical and Computer Engineering (L T Olana BSc), Addis Ababa University, Addis Ababa, Ethiopia; Yale School of Public Health - Social and Behavioral Sciences (E E Spurlock), Yale University, New Haven, CT, USA; Institute of Public Health (R Topor-Madry PhD), Jagiellonian University Medical College, Kraków, Poland; Agency for Health Technology Assessment and Tariff System, Warsaw, Poland (R Topor-Madry); Department of Epidemiology (K E Wiens PhD), Johns Hopkins University, Baltimore, MD, USA; Cochrane South Africa (Prof C S Wiysonge MD), South African Medical Research Council, Cape Town, South Africa; School of Public Health and Family Medicine (Prof C S Wiysonge), University of Cape Town, Cape Town, South Africa; National Data Management Center for Health (N A Worku MSc), Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Contributors Please see appendix 1 (section 12) for more detailed information about individual author contributions to the research, divided into the following categories: managing the estimation or publication process; writing the first draft of the manuscript; primary responsibility for applying analytical methods to produce estimates; primary responsibility for seeking, cataloguing, extracting, or cleaning data; designing or coding figures; providing data or critical feedback on data sources; developing methods or computational machinery; providing critical feedback on methods or results; drafting the manuscript or revising it critically for important intellectual content; and managing the overall research enterprise. Members of the core research team for this topic area had full access to the underlying data used to generate estimates presented in this paper. All other authors had access to, and reviewed, estimates as part of the research evaluation process.
Declaration of interests C Adolph reports support for the present manuscript from the Benificus Foundation for collection of data on state level social distancing policies in the USA. X Dai reports support for the present manuscript from paid salary through their employment at the Institute for Health Metrics and Evaluation and the University of Washington. A Flaxman reports stock or stock options from Agathos for technical advising on health metrics; and other support from Janssen, SwssRe, Merck for Mothers, and Sanofi for technical advising on simulation modelling, all outside the submitted work. N Fullman reports funding support for work unrelated to this Article from WHO as a consultant from June to September, 2019, and Gates Ventures since June, 2020, all outside the submitted work. S Nomura reports support for the present manuscript from a Ministry of Education, Culture, Sports, Science and Technology of Japan grant. D M Pigott reports support for the present manuscript from the Bill & Melinda Gates Foundation. All other authors declare no competing interests.
Data sharing To download the data used in these analyses, please visit the Global Health Data Exchange website (http://ghdx.healthdata.org/record/ihmedata/covid_19_cumulative_infections). Data sources are also listed by location and institution in appendix 2.
Acknowledgments Funding was provided by the Bill & Melinda Gates Foundation, J Stanton, T Gillespie, and J and E Nordstrom. A J Ferrari is supported by a National Health and Medical Research Council Early Career Fellowship Grant APP1121516 and is employed by the Queensland Centre for Mental Health Research, which receives core funding from the Queensland Department of Health. S Nomura would like to acknowledge the Ministry of Education, Culture, Sports, Science and Technology of Japan. R C Reiner Jr was partly supported by the National Science Foundation (award FAIN: 2031096). AL P Ribeiro

2378

www.thelancet.com Vol 399 June 25, 2022

Articles

was partly supported by CNPq (310679/2016-8 and 465518/2014-1), by FAPEMIG (PPM-00428-17 and RED-00081-16) and CAPES (88887.507149/2020-00). D F Santomauro is employed by the Queensland Centre for Mental Health Research, which receives core funding from the Department of Health, Queensland Government. C S Wiysonge's work is supported by the South African Medical Research Council.
References 1 Bjørnstad ON, Shea K, Krzywinski M, Altman N. Modeling
infectious epidemics. Nat Methods 2020; 17: 455-56.
2 Bjørnstad ON, Shea K, Krzywinski M, Altman N. The SEIRS model for infectious disease dynamics. Nat Methods 2020; 17: 557-58.
3 Cintrón-Arias A, Castillo-Chávez C, Bettencourt LMA, Lloyd AL, Banks HT. The estimation of the effective reproductive number from disease outbreak data. Math Biosci Eng 2009; 6: 261-82.
4 Friedman J, Liu P, Troeger CE, et al. Predictive performance of international COVID-19 mortality forecasting models. Nat Commun 2021; 12: 2609.
5 Bollyky TJ, Murray CJL, Reiner RC Jr. Epidemiology, not geopolitics, should guide COVID-19 vaccine donations. Lancet 2021; 398: 97-99.
6 Buss LF, Prete CA Jr, Abrahim CMM, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 2021; 371: 288-92.
7 US Centers for Disease Control and Prevention. Estimated COVID-19 infections, symptomatic illnesses, hospitalizations, and deaths in the United States. 2021. https://www.cdc.gov/coronavirus/2019-ncov/ cases-updates/burden.html (accessed June 24, 2021).
8 García-García D, Vigo MI, Fonfría ES, Herrador Z, Navarro M, Bordehore C. Retrospective methodology to estimate daily infections from deaths (REMEDID) in COVID-19: the Spain case study. Sci Rep 2021; 11: 11274.
9 Salje H, Tran Kiem C, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France. Science 2020; 369: 208-11.
10 Irons NJ, Raftery AE. Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests, and random surveys. Proc Natl Acad Sci USA 2021; 118: e2103272118.
11 Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA Intern Med 2020; 180: 1576-86.
12 Jones JM, Stone M, Sulaeman H, et al. Estimated US infectionand vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020-May 2021. JAMA 2021; 326: 1400-09.
13 Noh J, Danuser G. Estimation of the fraction of COVID-19 infected people in U.S. states and countries worldwide. PLoS One 2021; 16: e0246772.
14 Lewis HC, Ware H, Whelan M, et al. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. medRxiv 2022; published online Feb 15. https://doi. org/10.1101/2022.02.14.22270934 (preprint).
15 Chen X, Chen Z, Azman AS, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health 2021; 9: e598-609.
16 COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet 2022; published online March 10. https://doi.org/10.1016/S0140-6736(21)02796-3.
17 Institute for Health Metrics and Evaluation. Estimation of total and excess mortality due to COVID-19. 2021. http://www.healthdata.org/ special-analysis/estimation-excess-mortality-due-covid-19-andscalars-reported-covid-19-deaths (accessed Oct 15, 2021).
18 Kontis V, Bennett JE, Rashid T, et al. Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries. Nat Med 2020; 26: 1919-28.
19 WHO. The true death toll of COVID-19: estimating global excess mortality. 2021. https://www.who.int/data/stories/the-true-deathtoll-of-covid-19-estimating-global-excess-mortality (accessed June 15, 2021).
20 WHO. WHO coronavirus (COVID-19) dashboard. 2021. https:// covid19.who.int (accessed June 15, 2021).
21 Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: design, definitions, and metrics. Lancet 2012; 380: 2063-66.

22 Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet 2016; 388: e19-23.
23 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20: 533-34.
24 Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ 2021; 99: 19-33F.
25 Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol 2020; 35: 1123-38.
26 Arora RK, Joseph A, Van Wyk J, et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. Lancet Infect Dis 2021; 21: e75-76.
27 Eyre DW, Lumley SF, Wei J, et al. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status. Clin Microbiol Infect 2021; 27: e7-14.
28 Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet 2021; 397: 452-55.
29 Jolly B, Rophina M, Shamnath A, et al. Genetic epidemiology of variants associated with immune escape from global SARS-CoV-2 genomes. bioRxiv 2021; published online Dec 26. https://doi. org/10.1101/2020.12.24.424332 (preprint).
30 Lee J-S, Kim SY, Kim TS, et al. Evidence of severe acute respiratory syndrome coronavirus 2 reinfection after recovery from mild coronavirus disease 2019. Clin Infect Dis 2021; 73: e3002-08.
31 Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet 2021; 397: 1204-12.
32 Muecksch F, Wise H, Batchelor B, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis 2021; 223: 389-98.
33 Peluso MJ, Takahashi S, Hakim J, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv 2021; 7: eabh3409.
34 Perez-Saez J, Zaballa M-E, Yerly S, et al. Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect 2021; 27: 1695.e7-95.e12.
35 US Food and Drug Administration. EUA authorized serology test performance. 2021. https://www.fda.gov/medical-devices/ coronavirus-disease-2019-covid-19-emergency-use-authorizationsmedical-devices/eua-authorized-serology-test-performance (accessed June 18, 2021).
36 Xu B, Gutierrez B, Mekaru S, et al. Epidemiological data from the COVID-19 outbreak, real-time case information. Sci Data 2020; 7: 106.
37 Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis 2020; 71: 2027-34.
38 Miller TE, Garcia Beltran WF, Bard AZ, et al. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. FASEB J 2020; 34: 13877-84.
39 Jiang C, Wang Y, Hu M, et al. Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Transl Immunology 2020; 9: e1182.
40 COVID-19 Forecasting Team. Variation in the COVID-19 infection- fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. Lancet 2022; published online Feb 24. https:// doi.org/10.1016/S0140-6736(21)02867-1.
41 Roth GA, Emmons-Bell S, Alger HM, et al. Trends in patient characteristics and COVID-19 in-hospital mortality in the United States during the COVID-19 pandemic. JAMA Netw Open 2021; 4: e218828.
42 Zheng P, Barber R, Sorensen RJD, Murray CJL, Aravkin AY. Trimmed constrained mixed effects models: formulations and algorithms. J Comput Graph Stat 2021; 0: 1-13.
43 Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204-22.

www.thelancet.com Vol 399 June 25, 2022

2379

Articles

44 US Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19). 2020. https://www.cdc.gov/ coronavirus/2019-ncov/science/science-briefs/underlying-evidencetable.html (accessed Oct 18, 2021).
45 PRA Health Sciences. A global healthcare intelligence partner. 2021. https://prastudies.com/ (accessed June 29, 2021).
46 Secretaria de Vigilância em Saúde. Banco de dados de síndrome respiratória aguda grave--incluindo dados da COVID-19. https:// opendatasus.saude.gov.br/dataset/srag-2021-e-2022 (accessed Nov 2, 2020).
47 Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 2021; 372: n579.
48 Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science 2020; 369: 413-22.
49 Qualls N, Levitt A, Kanade N, et al. Community mitigation guidelines to prevent pandemic influenza--United States, 2017. MMWR Recomm Rep 2017; 66: 1-34.
50 Reiner RC Jr, Barber RM, Collins JK, et al. Modeling COVID-19 scenarios for the United States. Nat Med 2021; 27: 94-105.
51 Kretzschmar ME, Rozhnova G, Bootsma MCJ, van Boven M, van de Wijgert JHHM, Bonten MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. Lancet Public Health 2020; 5: e452-59.
52 Ferretti L, Wymant C, Kendall M, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science 2020; 368: eabb6936.
53 Yaqinuddin A. Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities. Med Hypotheses 2020; 144: 110049.
54 Yarmol-Matusiak EA, Cipriano LE, Stranges S. A comparison of COVID-19 epidemiological indicators in Sweden, Norway, Denmark, and Finland. Scand J Public Health 2021; 49: 69-78.
55 Adekunle A, Meehan M, Rojas-Alvarez D, Trauer J, McBryde E. Delaying the COVID-19 epidemic in Australia: evaluating the effectiveness of international travel bans. Aust N Z J Public Health 2020; 44: 257-59.
56 Jefferies S, French N, Gilkison C, et al. COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study. Lancet Public Health 2020; 5: e612-23.
57 King EJ, Dudina VI. COVID-19 in Russia: should we expect a novel response to the novel coronavirus? Glob Public Health 2021; 16: 1237-50.
58 Blavatnik School of Government, University of Oxford. Relationship between number of COVID-19 cases and government response. 2021. https://covidtracker.bsg.ox.ac.uk/stringency-scatter (accessed June 29, 2021).

59 Tran TPT, Le TH, Nguyen TNP, Hoang VM. Rapid response to the COVID-19 pandemic: Vietnam government's experience and preliminary success. J Glob Health 2020; 10: 020502.
60 Nguyen TA, Nguyen BTC, Duong DT, Marks GB, Fox GJ. Experience in responding to COVID-19 outbreaks from Vietnam. Lancet Reg Health West Pac 2021; 7: 100077.
61 Marome W, Shaw R. COVID-19 response in Thailand and its implications on future preparedness. Int J Environ Res Public Health 2021; 18: 1089.
62 US Centers for Disease Control and Prevention. Stay up to date with your COVID-19 vaccines. 2021. https://www.cdc.gov/ coronavirus/2019-ncov/vaccines/fully-vaccinated.html (accessed June 29, 2021).
63 Huang Y, Lu Y, Huang Y-M, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism 2020; 113: 154378.
64 Dennis JM, McGovern AP, Vollmer SJ, Mateen BA. Improving survival of critical care patients with coronavirus disease 2019 in England: a national cohort study, March to June 2020. Crit Care Med 2021; 49: 209-14.
65 Horwitz LI, Jones SA, Cerfolio RJ, et al. Trends in COVID-19 risk-adjusted mortality rates. J Hosp Med 2021; 16: 90-92.
66 Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020; 324: 1330-41.
67 Monedero P, Gea A, Castro P, et al. Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study. Crit Care 2021; 25: 2.
68 Wang Y, Li P, Solanki K, et al. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Virology 2021; 564: 33-38.
69 Merck. Merck and Ridgeback's investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study. 2021. https://www.merck.com/news/merck-and-ridgebacksinvestigational-oral-antiviral-molnupiravir-reduced-the-risk-ofhospitalization-or-death-by-approximately-50-percent-compared-toplacebo-for-patients-with-mild-or-moderat/ (accessed Oct 28, 2021).
70 Gazit S, Shlezinger R, Perez G, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv 2021; published online Aug 25. https://doi.org/10.1101/2021.08.24.21262415 (preprint).
71 Pulliam JRC, Schalkwyk C van, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the omicron variant in South Africa. medRxiv 2021; published online Dec 2. https://doi.org/10.1101/2021.11.11.21266068 (preprint).

2380

www.thelancet.com Vol 399 June 25, 2022

